<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004210689
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Vittoria-HCT
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALSARTAN,HYDROCHLOROTHIAZIDE,AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        160,12.5,5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        46.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DB01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        C09DA03
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vittoria HCT&trade; tablets contain three substances called amlodipine,<br />valsartan and hydrochlorothiazide. All of these substances help to control<br />high blood pressure.<br />- Amlodipine belongs to a group of substances called &ldquo;calcium channel<br />blockers&rdquo;. Amlodipine stops calcium from moving into the blood vessel<br />wall, which stops the blood vessels from tightening.<br />- Valsartan belongs to a group of substances called &ldquo;angiotensin-II receptor<br />antagonists&rdquo;. Angiotensin II is produced by the body and makes the blood<br />vessels tighten, thus increasing the blood pressure. Valsartan works by<br />blocking the effect of angiotensin II.<br />- Hydrochlorothiazide belongs to a group of substances called &ldquo;thiazide<br />diuretics&rdquo;. Hydrochlorothiazide increases urine output, which also lowers<br />blood pressure.<br />As a result of all three mechanisms, the blood vessels relax and blood<br />pressure is lowered.<br />Vittoria HCT&trade; is used to treat high blood pressure in adult patients whose<br />blood pressure is already controlled while taking amlodipine, valsartan and<br />hydrochlorothiazide and who may benefit from taking one tablet containing<br />all three substances.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Vittoria HCT&trade;<br />- if you are more than 3 months pregnant. (It is also recommended to avoid<br />Vittoria HCT&trade; in early pregnancy - see Pregnancy section.)<br />- if you are allergic to amlodipine or to any other calcium channel blockers,<br />valsartan, hydrochlorothiazide, sulphonamide-derived medicines<br />(medicines used to treat chest or urinary infections), or any of the other<br />ingredients of this medicine (listed in section 6).<br />If you think you may be allergic, do not take Vittoria HCT&trade; and talk to<br />your doctor.<br />- if you have liver disease, destruction of the small bile ducts within the<br />liver (biliary cirrhosis) leading to the build up of bile in the liver<br />(cholestasis).<br />- if you have severe kidney problems or if you are having dialysis.<br />- if you are unable to produce urine (anuria).<br />- if the level of potassium or sodium in your blood is too low despite<br />treatment to increase the potassium or sodium levels in your blood.<br />- if the level of calcium in your blood is too high despite treatment to<br />reduce the calcium levels in your blood.<br />- if you have gout (uric acid crystals in the joints).<br />- if you have severe low blood pressure (hypotension).<br />- if you have narrowing of the aortic valve (aortic stenosis) or cardiogenic<br />shock (a condition where your heart is unable to supply enough blood to<br />the body).<br />- if you suffer from heart failure after a heart attack.<br />- if you have diabetes or impaired kidney function and you are treated with<br />a blood pressure lowering medicine containing aliskiren.<br />If any of the above applies to you, do not take Vittoria HCT&trade; and talk<br />to your doctor.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Vittoria HCT&trade;<br />- if you have a low level of potassium or magnesium in your blood (with or<br />without symptoms such as muscle weakness, muscle spasms, abnormal<br />heart rhythm).<br />- if you have a low level of sodium in your blood (with or without<br />symptoms such as tiredness, confusion, muscle twitching, convulsions).<br />- if you have a high level of calcium in your blood (with or without<br />symptoms such as nausea, vomiting, constipation, stomach pain, frequent<br />urination, thirst, muscle weakness and twitching).<br />- if you have kidney problems, have had a kidney transplant or if you had<br />been told that you have a narrowing of your kidney arteries.<br />- if you have liver problems.<br />- if you have or have had heart failure or coronary artery disease,<br />particularly.<br />- if you have experienced a heart attack. Follow your doctor&rsquo;s instructions<br />for the starting dose carefully. Your doctor may also check your kidney<br />function.<br />- if your doctor has told you that you have a narrowing of the valves in<br />your heart (called &ldquo;aortic or mitral stenosis&rdquo;) or that the thickness of your<br />heart muscle is abnormally increased (called &ldquo;obstructive hypertrophic<br />cardiomyopathy&rdquo;).<br />- if you suffer from aldosteronism. This is a disease in which the adrenal<br />glands make too much of the hormone aldosterone If this applies to you,<br />the use of Vittoria HCT&trade; is not recommended.<br />- if you suffer from a disease called systemic lupus erythematosus (also<br />called &ldquo;lupus&rdquo; or &ldquo;SLE&rdquo;).<br />- if you have diabetes (high level of sugar in your blood). - if you have high<br />levels of cholesterol or triglycerides in your blood.<br />- if you experience skin reactions such as rash after sun exposure.<br />- if you had an allergic reaction to other high blood pressure medicines or<br />diuretics (a type of medicine also known as &ldquo;water tablets&rdquo;), especially if<br />you suffer from asthma and allergies<br />- if you have been sick (vomiting or diarrhoea).<br />- if you have experienced swelling, particularly of the face and throat,<br />while taking other medicines (including angiotensin converting enzyme<br />inhibitors). If you get these symptoms, stop taking Vittoria HCT&trade; and<br />contact your doctor straight away. You should never take<br />Vittoria HCT&trade; again.<br />- if you experience dizziness and/or fainting during treatment with<br />Vittoria HCT&trade;, tell your doctor as soon as possible.<br />- if you experience a decrease in vision or eye pain. These could be<br />symptoms of an increase of pressure in your eye and can happen within<br />hours to a week of taking Vittoria HCT&trade;. This can lead to permanent<br />vision impairment, if not treated.<br />- if you are taking any of the following medicines used to treat high blood<br />pressure:<br />- an ACE inhibitor (for example enalapril, lisinopril, ramipril), in particular<br />if you have diabetes-related kidney problems. - aliskiren.<br />Your doctor may check your kidney function, blood pressure, and the<br />amount of electrolytes (e.g. potassium) in your blood at regular intervals.<br />See also information under the heading &ldquo;Do not take Vittoria HCT&trade;&rdquo;.<br />If any of these apply to you, talk to your doctor.<br />Children and adolescents<br />The use of Vittoria HCT&trade; in children and adolescents under 18 years of<br />age is not recommended.<br />Elderly people (age 65 years and older)<br />Vittoria HCT&trade; can be used by people aged 65 years and over at the same<br />dose as for other adults and in the same way as they have already taken the<br />three substances called amlodipine, valsartan and hydrochlorothiazide.<br />Elderly patients, particularly those taking the maximum dose should have<br />their blood pressure checked regularly.<br />Other medicines and Vittoria HCT&trade;<br />Tell your doctor or pharmacist if you are taking, have recently taken or<br />might take any other medicines. Your doctor may need to change your dose<br />and/or to take other precautions. In some cases you may have to stop using<br />one of the medicines. This is especially important if you are using any of<br />the medicines listed below:<br />Do not take together with:<br />&bull; lithium (a medicine used to treat some types of depression);<br />&bull; medicines or substances that increase the amount of potassium in your<br />blood. These include potassium supplements or salt substitutes containing<br />potassium, potassium-sparing medicines and heparin;<br />&bull; ACE inhibitors or aliskiren (see also information under the headings<br />&ldquo;Do not take Vittoria HCT&trade;&rdquo; and &ldquo;Warnings and precautions&rdquo;).<br />Caution should be used with:<br />&bull; alcohol,sleepingpillsandanaesthetics(medicines allowing patients to<br />undergo surgery and other procedures);<br />&bull; amantadine (anti-Parkinson therapy, also used to treat or prevent certain<br />illnesses caused by viruses);<br />&bull; anticholinergic agents (medicines used to treat a variety of disorders such<br />as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness,<br />muscular spasms, Parkinson&#39;s disease and as an aid to anaesthesia);<br />&bull; anticonvulsant medicines and mood-stabilising medicines used to treat<br />epilepsy and bipolar disorder (e.g. carbamazepine, phenobarbital,<br />phenytoin, fosphenytoin, primidone);<br />&bull; cholestyramine, colestipol or other resins (substances used mainly to treat<br />high levels of lipids in the blood);<br />&bull; simvastatin (a medicine used to control high cholesterol levels);<br />&bull; ciclosporin (a medicine used in transplantation to prevent organ rejection<br />or for other conditions, e.g: rheumatoid arthritis or atopic dermatitis);<br />&bull; cytotoxic medicines (used to treat cancer), such as methotrexate or<br />cyclophosphamide;<br />&bull; digoxin or other digitalis glycosides (medicines used to treat heart<br />problems);<br />&bull; verapamil, diltiazem (heart medicines);<br />&bull; iodine contrast media (agents used for imaging examinations);<br />&bull; medicines for the treatment of diabetes (oral agents such as metformin or<br />insulins);<br />&bull; medicines for the treatment of gout, such as allopurinol; medicines that<br />may increase blood sugar levels (beta blockers, diazoxide);<br />&bull; medicines that may induce &ldquo;torsades de pointes&rdquo; (irregular heart beat),<br />such as antiarrhythmics (medicines used to treat heart problems) and some<br />antipsychotics;<br />&bull; medicines that may reduce the amount of sodium in your blood, such as<br />antidepressants, antipsychotics, antiepileptics;<br />&bull; medicines that may reduce the amount of potassium in your blood, such<br />as diuretics (water tablets), corticosteroids, laxatives, amphotericin or<br />penicillin G;<br />&bull; medicines to increase blood pressure such as adrenaline or noradrenaline;<br />medicines used for HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir);<br />&bull; medicines used to treat fungal infections (e.g. ketoconazole, itraconazole);<br />medicines used for oesophageal ulceration and inflammation<br />(carbenoxolone);<br />&bull; medicines used to relieve pain or inflammation, especially non-steroidal<br />anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2<br />inhibitors (Cox-2 inhibitors);<br />&bull; muscle relaxants (medicines to relax the muscles which are used during<br />operations);<br />&bull; nitroglycerin and other nitrates, or other substances called &ldquo;vasodilators&rdquo;;<br />&bull; other medicines to treat high blood pressure, including methyldopa;<br />&bull; rifampicin (used, for example, to treat tuberculosis), erythromycin,<br />clarithromycin (antibiotics);<br />&bull; St. John&rsquo;s wort;<br />&bull; dantrolene (infusion for severe body temperature abnormalities);<br />&bull; vitamin D and calcium salts.<br />Vittoria HCT&trade; with food, drink and alcohol<br />Grapefruit and grapefruit juice should not be consumed by people who are<br />prescribed Vittoria HCT&trade;. This is because grapefruit and grapefruit juice<br />can lead to an increase in the blood levels of the active substance<br />amlodipine, which can cause an unpredictable increase in the blood<br />pressure lowering effect of Vittoria HCT&trade;. Talk to your doctor before<br />drinking alcohol. Alcohol may make your blood pressure fall too much<br />and/or increase the possibility of dizziness or fainting.<br />Pregnancy and breast-feeding<br />Pregnancy<br />You must tell your doctor if you think you are (or might become) pregnant.<br />Your doctor will normally advise you to stop taking Vittoria HCT&trade; before<br />you become pregnant or as soon as you know you are pregnant and will<br />advise you to take another medicine instead of Vittoria HCT&trade;.<br />Vittoria HCT&trade; is not recommended in early pregnancy and must not be<br />taken when more than 3 months pregnant, as it may cause serious harm to<br />your baby if used after the third month of pregnancy.<br />Breast-feeding<br />Tell your doctor if you are breast-feeding or about to start breast-feeding.<br />Amlodipine has been shown to pass into breast milk in small amounts.<br />Vittoria HCT&trade; is not recommended for mothers who are breast-feeding,<br />and your doctor may choose another treatment for you if you wish to<br />breast-feed, especially if your baby is a newborn, or was born prematurely.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />Driving and using machines<br />This medicine may make you feel dizzy, drowsy, nauseous or have a<br />headache. If you experience these symptoms, do not drive or use tools or<br />machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with<br />your doctor if you are not sure. This will help you get the best results and<br />lower the risk of side effects.<br />The usual dose of Vittoria HCT&trade; is one tablet per day.<br />- It is best to take the tablet at the same time each day.<br />Morning is the best time.<br />- Swallow the tablet whole with a glass of water.<br />- You can take Vittoria HCT&trade; with or without food. Do not take<br />Vittoria HCT&trade; with grapefruit or grapefruit juice.</p><p>Depending on how you respond to the treatment, your doctor may suggest<br />a higher or lower dose.<br />Do not exceed the prescribed dose.<br />If you take more Vittoria HCT&trade; than you should<br />If you have accidentally taken too many Vittoria HCT&trade; tablets, talk to a<br />doctor immediately.You may require medical attention.<br />If you forget to take Vittoria HCT&trade;<br />If you forget to take a dose of this medicine, take it as soon as you<br />remember and then take the next dose at its usual time. If it is almost time<br />for your next dose you should simply take the next tablet at the usual time.<br />Do not take a double dose (two tablets at once) to make up for a forgotten<br />tablet.<br />If you stop taking Vittoria HCT&trade;<br />Stopping your treatment with Vittoria HCT&trade; may cause your disease to<br />get worse.<br />Do not stop taking your medicine unless your doctor tells you to.<br />Always take this medicine, even if you are feeling well<br />People who have high blood pressure often do not notice any signs of the<br />problem. Many feel normal. It is very important that you take this<br />medicine exactly as your doctor tells you to get the best results and reduce<br />the risk of side effects. Keep your appointments with the doctor even if<br />you are feeling well. If you have any further questions on the use of this<br />medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />As for any combination containing three active substances, side effects<br />associated with each individual component cannot be excluded. The side<br />effects reported with Vittoria HCT&trade; or one of its three active substances<br />(amlodipine, valsartan and hydrochlorothiazide) are listed below and may<br />occur with the use of Vittoria HCT&trade;.<br />Some side effects can be serious and need immediate medical<br />attention. Consult a doctor immediately if you experience any<br />of the following serious side effects after taking this medicine:<br />Common (may affect up to 1 in 10 people):<br />&bull; dizziness, &bull; low blood pressure (feeling of faintness, lightheadedness,<br />sudden loss of consciousness)<br />Uncommon (may affect up to 1 in 100 people):<br />&bull; severelydecreasedurineoutput(decreasedkidney function)<br />Rare (may affect up to 1 in 1,000 people):<br />&bull; spontaneousbleeding &bull; irregularheartbeat &bull; liverdisorder<br />Very rare (may affect up to 1 in 10,000 people):<br />&bull; sudden wheeziness, chest pain, shortness of breath or difficulty breathing,<br />&bull; swelling of eyelids, face or lips, &bull; swelling of the tongue and throat which<br />causes great difficulty breathing , &bull; severe skin reactions including intense<br />skin rash, hives, reddening of the skin over your whole body, severe<br />itching, blistering, peeling and swelling of the skin, inflammation of the<br />mucous membranes (Stevens-Johnson syndrome, toxic epidermal<br />necrolysis) or other allergic reactions, &bull; heart attack, &bull; inflamed pancreas,<br />which may cause severe abdominal and back pain accompanied with<br />feeling of being very unwell, &bull; weakness, bruising, fever and frequent<br />infections, &bull; stiffness<br />Other side effects may include:<br />Very common (may affect more than 1 in 10 people):<br />&bull; lowlevelofpotassiumintheblood &bull; increaseoflipidsintheblood<br />Common (may affect up to 1 in 10 people):<br />&bull; sleepiness, &bull; palpitations (awareness of your heart beat) &bull; flushing<br />&bull; ankle swelling (oedema), &bull; abdominal pain, &bull; stomach discomfort after<br />meal, &bull; tiredness, &bull; headache, &bull; frequent urination, &bull; high level of uric acid<br />in the blood, &bull; low level of magnesium in the blood, &bull; low level of sodium<br />in the blood, &bull; dizziness, fainting on standing up, &bull; reduced appetite,<br />&bull; nausea and vomiting, &bull; itchy rash and other types of rash<br />&bull; inability to achieve or maintain erection<br />Uncommon (may affect up to 1 in 100 people):<br />&bull; fastheartbeat, &bull; spinning sensation, &bull; vision disorder, &bull; stomach<br />discomfort, &bull; chest pain, &bull; increase of urea nitrogen, creatinine and uric<br />acid in the blood, &bull; high level of calcium, fat or sodium in the blood<br />&bull; decrease of potassium in the blood, &bull; breath odour, &bull; diarrhoea, &bull; dry<br />mouth, &bull; weight increase, &bull; loss of appetite, &bull; disturbed sense of taste<br />&bull; back pain, &bull; joint swelling, &bull; muscle cramps/weakness/pain, &bull; pain in<br />extremity, &bull; inability to either stand or walk in a normal manner<br />&bull; weakness, &bull; abnormal coordination, &bull; dizziness on standing up or after<br />exercising, &bull; lack of energy, &bull; sleep disturbances, &bull; tingling or numbness<br />&bull; neuropathy, &bull; sudden, temporary loss of consciousness, &bull; low blood<br />pressure on standing up, &bull; cough, &bull; breathlessness, &bull; throat irritation<br />&bull; excessive sweating, &bull; itching, &bull; swelling, reddening and pain along a vein,<br />&bull; skin reddening, &bull; trembling, &bull; mood changes, &bull; anxiety, &bull; depression,<br />&bull; sleeplessness, &bull; taste abnormalities, &bull; fainting, &bull; loss of pain sensation,<br />&bull; visual disturbances, &bull; visual impairment, &bull; ringing in the ears,<br />&bull; sneezing/runny nose caused by inflammation of the lining of the nose<br />(rhinitis), &bull; altered bowel habits, &bull; indigestion, &bull; hair loss, &bull; itchy skin,<br />&bull; skin discolouration, &bull; disorder in passing urine<br />&bull; increased need to urinate at night,<br />&bull; increasednumberoftimesofpassingurine,<br />&bull; discomfortorenlargementofthebreastsinmen &bull; pain, &bull; feelingunwell,<br />&bull; weightdecrease<br />Rare (may affect up to 1 in 1,000 people):<br />&bull; lowlevelofbloodplatelets(sometimeswithbleedingor bruising underneath<br />the skin), &bull; sugar in the urine, &bull; high level of sugar in the blood,<br />&bull; worsening of the diabetic metabolic state, &bull; abdominal discomfort,<br />&bull; constipation, &bull; liver disorders which can occur together with yellow skin<br />and eyes, or dark-coloured urine (haemolytic anaemia), &bull; increased<br />sensitivity of skin to sun ,&bull; purple skin patches, &bull; kidney disorders,<br />&bull; confusion<br />Very rare (may affect up to 1 in 10,000 people):<br />&bull; decreasednumberofwhitebloodcells, &bull; decrease in blood platelets which<br />may result in unusual brusing or easy bleeding (red blood cell damage)<br />&bull; swelling of the gums, &bull; abdominal bloating (gastritis), &bull; inflammation of<br />the liver (hepatitis), &bull; yellowing of the skin (jaundice), &bull; liver enzyme<br />increase which may have an effect on some medical tests, &bull; increased<br />muscle tension, &bull; inflammation of blood vessels often with skin rash,<br />&bull; sensitivity to light &bull; disorders combining rigidity, tremor and/or<br />movement disorders, &bull; fever, sore throat or mouth ulcers, more frequent<br />infections (lack or low level of white blood cells), &bull; pale skin, tiredness,<br />breathlessness, dark-coloured urine (haemolytic anaemia, abnormal<br />breakdown of red blood cells either in the blood vessels or elsewhere in the<br />body), &bull; confusion, tiredness, muscle twitching and spasm, rapid breathing<br />(hypochloraemic alkalosis), &bull; severe upper stomach ache (inflammation of<br />the pancreas), &bull; difficulty breathing with fever, coughing, wheezing,<br />breathlessness (respiratory distress, pulmonary oedema, pneumonitis),<br />&bull; facial rash, joint pain, muscle disorder, fever (lupus erythematosus),<br />&bull; inflammation of blood vessels with symptoms such as rash, purplish-red<br />spots, fever (vasculitis), &bull; severe skin disease that causes rash, red skin,<br />blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal<br />necrolysis)<br />Not known (frequency cannot be estimated from the available data):<br />&bull; changesin blood tests for kidney function, increase of potassium in your<br />blood, low level of red blood cells, &bull; abnormal red blood cell test<br />&bull; low level of a certain type of white blood cell and blood platelet<br />&bull; increase of creatinine in the blood, &bull; abnormal liver function test<br />&bull; severely decreased urine output, &bull; inflammation of blood vessels<br />&bull; weakness, bruising and frequent infections (aplastic anaemia)<br />&bull; decrease in vision or pain in your eyes due to high pressure (possible<br />signs of acute angle-closure glaucoma), &bull; breathlessness, &bull; severely<br />decreased urine output (possible signs of renal disorder or renal failure)<br />&bull; severe skin disease that causes rash, red skin, blistering of the lips, eyes<br />or mouth, skin peeling, fever (erythema multiforme), &bull; muscle spasm,<br />&bull; fever (pyrexia), &bull; blistering skin (sign of a condition called dermatitis<br />bullous)<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes<br />any possible side effects not listed in this leaflet. By reporting side effects<br />you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.<br />&bull; Do not use this medicine after the expiry date which is stated on the<br />carton and blister after EXP.<br />&bull; Do not store above 30&deg;C.<br />&bull; Store in the original package in order to protect from moisture.<br />&bull; Do not use any Vittoria HCT&trade; pack that is damaged or shows signs of<br />tampering.<br />&bull; Do not throw away any medicines via wastewater or household waste.<br />Ask your pharmacist how to throw away medicines you no longer use.<br />These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Vittoria HCT&trade; contains<br />The active substances of Vittoria HCT&trade; are amlodipine (as amlodipine<br />besylate), valsartan and hydrochlorothiazide.<br />Vittoria HCT&trade; 10/160/25 mg Film Coated Tablets:<br />Each film coated tablet contains 10 mg of Amlodipine as Amlodipine<br />Besilate, 160 mg of Valsartan and 25 mg of Hydrochlorothiazide.<br />Vittoria HCT&trade; 5/160/25 mg Film Coated Tablets:<br />Each film coated tablet contains 5 mg of Amlodipine as Amlodipine<br />Besilate, 160 mg of Valsartan and 25 mg of Hydrochlorothiazide.<br />Vittoria HCT&trade; 5/160/12.5 mg Film Coated Tablets:<br />Each film coated tablet contains 5 mg of Amlodipine as Amlodipine<br />Besilate, 160 mg of Valsartan and 12.5 mg of Hydrochlorothiazide.<br />Other ingredients are:<br />Vittoria HCT&trade; 10/160/25 mg Film Coated Tablets:<br />Microcrystalline cellulose, Crospovidone, Colloidal silicon dioxide,<br />Magnesium stearate, Hypromellose, Iron oxide Yellow, Macrogal,<br />Titanium dioxide, Talc and Sunset Yellow Lake.<br />Vittoria HCT&trade; 5/160/25 mg Film Coated Tablets:<br />Microcrystalline cellulose, Crospovidone, Colloidal silicon dioxide,<br />Magnesium stearate, Hypromellose, Iron oxide Yellow,<br />Macrogal,Titanium dioxide, Talc and Sunset Yellow Lake.<br />Vittoria HCT&trade; 5/160/12.5 mg Film Coated Tablets:<br />Microcrystalline cellulose, Crospovidone, Colloidal silicon dioxide,<br />Magnesium stearate, Hypromellose, Titanium dioxide, Macrogal and Talc.<br />What Vittoria HCT&trade; looks like and contents of the pack<br />Vittoria HCT&trade; 10/160/25 mg Film Coated Tablets: Yellow colored,<br />Ovaloid, Biconvex film coated tablets, Debossed with &lsquo;158&rsquo; on one side<br />and &lsquo;JP&rsquo; on other side.<br />Vittoria HCT&trade; 5/160/25 mg Film Coated Tablets: Brown Yellow<br />colored, Ovaloid, Biconvex film coated tablets, Debossed with &lsquo;157&rsquo; on<br />one side and &lsquo;JP&rsquo; on other side.<br />Vittoria HCT&trade; 5/160/12.5 mg Film Coated Tablets: White to off white<br />colored, Ovaloid, Biconvex film coated tablets, Debossed with &lsquo;156&rsquo; on<br />one side and &lsquo;JP&rsquo; on other side.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vittoria HCT™ tablet are available in the following packs:
10/160/25 mg are available in a box of 4 blisters, 7 tablets per each blister.
5/160/25 mg are available in a box of 4 blisters, 7 tablets per each blister.
5/160/12.5 mg are available in a box of 4 blisters, 7 tablets per each blister.
Not all packs may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co.,<br />Jeddah, Makkah region, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa o Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>على ثلاث مواد &quot; أملودیبین/ فالسارتان/ ھیدروكلوروثیازید&quot;. &trade; یحتوي فیتوریا إتش سي تي<br />تُساعد ھذه المواد على التحكم في ارتفاع ضغط الدَّم.<br />- ینتمي أملودیبین إلى مجموعة من المواد تسمى &quot;حاصرات قنوات الكالسیوم&quot;. حیث یقوم<br />أملودیبین بمنع الكالسیوم من الانتقال إلى جدار الأوعیة الدمویة مما یمنع الأوعیة الدمویة من<br />التضیُّق.<br />- ینتمي فالسارتان إلى مجموعة من الأدویة تسمى &quot;مضادات مستقبلات الأنجیوتینسن ۲&quot;. حیث<br />ینتج الجسم الأنجیوتینسین ۲ وھو ما یجعل الأوعیة الدمویة مضغوطة وضیّقة مما یؤدي إلى<br />. ارتفاع ضغط الدم. فیعمل فالسارتان عن طریق منع تأثیر أنجیوتنسین ۲<br />- ینتمي ھیدروكلوروثیازید إلى مجموعة من المواد تُسمى: &quot;مُدِرات البول الثیازیدیة&quot; أو أقراص<br />الماء. حیث یُزید ھیدروكلوروثیازید من إخراج البول، ویعمل على انخفاض ضغط الدَّم أیضًا.<br />ترتخي الأوعیة الدَّمویة وینخفض ضغط الدم نتیجة لتأثیر ھذه المواد الثلاث.<br />لعلاج ارتفاع ضغط الدم في المرضى من البالغین الذین یمكن &trade; یتم تناول فیتوریا إتش سي تي<br />التحكم في ضغط الدم لدیھم بعد تناول أملودیبین و فالسارتان و ھیدروكلوروثیازید ویمكن أن<br />یستفیدوا من تناول قرص واحد یحتوي على ھذه المواد الثلاث.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول فیتوریا إتش سي تي<br />&trade; - إذا كان حملكِ قد تجاوز الشھر الثالث، (فمن الأفضل أیضًا تجنُّب تناوُل فیتوریا إتش سي تي<br />في مراحل الحمل المُبكرة -انظريِ قسم: &quot;الحمل&quot;).<br />- إذا كنت تعاني من حساسیة تجاه أملودیبین أو أيِّ من حاصرات قنوات الكالسیوم أو فالسارتان أو<br />ھیدروكلوروثیازید أو الأدویة المشتقة من السلفونامید (أدویة تستخدم لعلاج عدوى الصدر والبول)<br />.( أو أيّ من المكونات الأخرى الداخلة في تركیب ھذا الدواء (المُدرجة في قسم ٦<br />إذا كنت تعتقد أنك قد تكون مصابًا بحساسیة ،&trade; - استشیر طبیبك ولا تتناول فیتوریا إتش سي تي<br />تجاه ھذا الدواء.<br />- إذا كنت تعاني من مرض كبدي وتلف القنوات الصفراویة الصغیرة داخل الكبد (تلیُّف الكبد<br />الصفراوي)؛ مما یُؤدي إلى تراكم العصارة الصفراویة في الكبد (ركود صفراوي).<br />- إذا كنت تعاني من مشاكل حادة بالكُلى أو تخضع للغسیل الكلوي.<br />- إذا كنت غیر قادر على التبوُّل (انحباس البول).<br />- إذا كان مستوى البُوتاسیوم أو الصودیوم في الدم أقل من الطبیعي، على الرغم من تلقي العلاج<br />لزیادة مستویات البوتاسیوم أو الصودیوم في الدم.<br />- إذا كان مستوى الكالسیوم في الدم أعلى من الطبیعي، على الرغم من تلقي العلاج لتقلیل<br />مستویات الكالسیوم في الدم.<br />- إذا كنت تعاني من مرض النقرس (بلورات حمض الیوریا التي توجد في المفاصل).<br />- إذا كنت تٌعاني من انخفاض حادّ في ضغط الدم (انخفاض ضغط الدم).<br />- إذا كنت تٌعاني من ضیْق في صمام القلب الأبھر (تضیّق الأبھر) أو صدمة قلبیة (الحالة التي<br />یكون فیھا القلب غیر قادر على إمداد الجسم بالدم الكافي).<br />- إذا كنت تُعاني من فشل القلب بعد الإصابة بأزمة قلبیة.<br />- إذا كنت مصابًا بداء السُّكَّري أو تُعاني من قصور في وظائف الكُلى، وتتناول عقار خافض<br />لضغط الدَّم یحتوي على ألیسكیرین.<br />إذا انطبق علیك أيٌّ من الحالات المذكورة أعلاه واستشر &trade; لا تتناول فیتوریا إتش سي تي<br />طبیبك.<br />تحذیرات واحتیاطات<br />في الحالات التالیة: &trade; استشر طبیبك أو الصیدلي قبل تناول فیتوریا إتش سي تي<br />- إذا كنت تعاني من انخفاض مستوى البوتاسیوم أو الماغنسیوم. في الدَّم (المصحوب في بعض<br />الأحیان بأعراض مثل ضعف العضلات أو تقلُّصات عضلیة أو اضطرابات في نظم القلب).<br />- إذا كنت تُعاني من انخفاض مستوى الصودیوم في الدّم (المصحوب في بعض الأحیان بأعراض<br />مثل شعور بالإرھاق أو ارتباك أو انتفاض العضلات أو تشنّجات)<br />- إذا كنت تعاني من ارتفاع مستوى الكالسیوم في الدم (المصحوب في بعض الأحیان بأعراض<br />مثل قيء أو إمساك أو ألم في المعدة أو زیادة إدرار البول أو عطش أو ضعف أو تشنّج العضلات).<br />- إذا كنت تعاني من مشاكل في الكلى أو أجریت عملیة زرع كلى أو إذا علمت أنك تعاني من<br />ضیْق في شرایین الكلى.<br />- إذا كنت تعاني من مشاكل بالكبد.<br />- إذا كُنت تعاني أو سبق أن عانیت من فشل القلب أو أمراض الشریان التاجي.<br />- إذا كنت تُعاني من أزمة قلبیة، قم باتباع تعلیمات طبیبك بشأن جُرعة البدء بدقّة وعنایة. وقد یقوم<br />طبیبك أیضًا بفحص وظائف الكُلى لدیك.<br />- إذا أخبرك طبیبك أن لدیك ضیقًا في صمامات القلب (والذي یُسمّى ب &quot; تَضَیُّقُ مِتْرالِي أو اَبْھَرِيّ<br />&quot;) أو أن سُمك عضلة القلب لدیك یزداد بشكل غیر طبیعي (والذي یُسمّى ب &quot;اعتلال عضلة القلب<br />الضخامي الانسدادي&quot;).<br />- إذا كُنت تُعَاني من الألدوستیرونیة (نوع من الاضطراب الھرموني الذي یؤدي إلى ارتفاع ضغط<br />الدم)؛ وھو مرض تُفرِز فیھ الغدد الكظریة كمیة كبیرة جدًّا من ھرمون الألدوستیرون. فإذا كان ھذا<br />.&trade; ینطبق علیك، فلا یُنصح بتناول فیتوریا إتش سي تي<br />.(SLE) - إذا كنت تعاني من مرض الذئبة الحمامیة الجھازیة<br />- إذا كنت تعاني من مرض السُّكَّرِي (ارتفاع مستوى السكر في الدم)، أو تعاني من ارتفاع<br />مُستویات الكولیسترول، أو الدھون الثلاثیة في الدّم.<br />- إذا كنت تعاني من تفاعلات جلدیة مثل طفح جلدي بعد التعرض للشمس.<br />- إذا كنت تعاني من تفاعلات حساسیة تجاه أدویة ارتفاع ضغط الدم أو مدرّات البول (وھي ما<br />تسمى بأقراص الماء، وخصوصًا إذا كنت تعاني من الربو والحساسیة).<br />- إذا كنت تعاني من الشعور بالدوار أو الغثیان (قيء أو إسھال).<br />- إذا كنت تعاني من التورّم وخاصةً في الوجھ والحلق أثناء تناول أدویة أخرى (بما في ذلك<br />مثبطات الإنزیم المحوّل للأنجیوتنسین). فإذا أُصِبت بأي من ھذه الأعراض، توقَّف عن تناوُل<br />واتصل بطبیبك على الفور. حیث یجب الامتناع عن تناول أقراص فیتوریا &trade; فیتوریا إتش سي تي<br />مرة أخرى. &trade; إتش سي تي<br />اتصل بطبیبك في ،&trade; - إذا أصِبت بدوخة و/أو إغماء أو إسھال أثناء تناول فیتوریا إتش سي تي<br />أسرع وقت ممكن.<br />- إذا تعرَّضت لضعف الرؤیة أو ألم بالعین. حیث یمكن أن تكون ھذه أعراض لزیادة ضغط العین،<br />ویُمكِن أن یُؤدي ذلك .&trade; وقد تحدث في غضون ساعات إلى أسبوع من تناوُل فیتوریا إتش سي تي<br />إلى ضعف البصر الدائم إذا لم یتم علاجھ.<br />- إذا كنت تتناول أیًّا من الأدویة التَّالیة التي تُستَخدَم لعلاج ارتفاع ضغط الدَّم:<br />- مثبّط الإنزیم المُحَوِّل للأنجیوتنسین (مثل: إنالابریل ولیزینوبریل ورامیبریل)؛ لا سیّما إذا كنت<br />تُعاني من مشاكل بالكُلى متعلقة بمرض السُّكَّري.- ألیسكیرین.<br />قد یفحص طبیبك وظائف الكُلى وضغط الدَّم لدیك وكمیة الكھارل (مثل: البوتاسیوم) في الدّم على<br />.&quot;.&trade; فترات منتظمة. انظر أیضًا المعلومات تحت عنوان: &quot;لا تتناول فیتوریا إتش سي تي<br />إذا كان أيٌّ من ھذه الأعراض تنطبق علیك، یُرجى التحدُّث إلى طبیبك.<br />المرضى من الأطفال والمراھقین<br />في المرضى من الأطفال والمراھقین الذین تقلّ أعمارھم &trade; لا یُوصى بتناول فیتوریا إتش سي تي<br />عن ۱۸ عامًا.<br />المرضى من كبار السنّ ( ٦٥ سنة فأكثر)<br />یمكن أن یتناول الأشخاص الذین تتراوح أعمارھم بین ٦٥ عامًا فأكثر نفس الجرعة المقررة<br />للمرضى من البالغین الذین یتناولون بالفعل المواد الثلاث أملودیبین وفالسارتان<br />وھیدروكلوروثیازید. حیث ینبغي على المرضى من كبار السن خاصة الذین یتناولون الجرعة<br />القصوى فحص ضغط الدم بانتظام.<br />&trade; تناول الأدویة الأخرى بالتزامن مع فیتوریا إتش سي تي<br />یُرجى إبلاغ طبیبك أو الصیدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أیَّة أدویة أخرى. قد<br />یحتاج طبیبك إلى تغییر الجرعة الخاصة بك و/أو اتخاذ احتیاطات أخرى. وقد تكون مضطرًّا في<br />بعض الحالات إلى التَّوقف عن تناوُل أحد الأدویة. وحیث یعتبر ذلك الأمر ھامّ بشكل خاص إذا<br />كنت تتناول أي من الأدویة الواردة فیما بعد:<br />بالتزامن مع الأدویة الآتیة: &trade; لا تتناول فیتوریا إتش سي تي<br />&bull; اللیثیوم (عقار یُستخدم لعلاج بعض أنواع الاكتئاب).<br />&bull; الأدویة أو المواد التي قد تُزید كمیة البوتاسیوم في الدم، ویشمل ھذا مُكمِّلات البوتاسیوم أو بدائل<br />الملح التي تحتوي على البوتاسیوم والأدویة المُوَفِّرة للبوتاسیوم والھیبارین.<br />&bull; مثبّطات الإنزیم المحوّل للأنجیوتنسین أو ألیسكیرین (انظر أیضا المعلومات الواردة تحت<br />و&quot; تحذیرات واحتیاطات&quot;). &quot;&trade; العناوین &quot;لا تتناول فیتوریا إتش سي تي<br />یجب توخّي الحذر عند تناول ما یلي:<br />&bull; الكحول والأقراص المنوّمة وأدویة التخدیر (الأدویة التي یتم إعطائھا للمرضى بغرض التخدیر<br />قبل الخضوع لعملیة جراحیة أو إجراءات طبیة أخرى).<br />&bull; أمانتادین (دواء یُستَخدَم لعلاج مرض الشلل الرعاش وأیضًا لعلاج بعض الأمراض الناجمة عن<br />الفیروسات أو الوقایة منھا).<br />&bull; الأدویة المُضادّة لإفراز الكولین (الأدویة التي تُستَخدَم لعلاج مجموعة متنوعة من الاضطرابات<br />مثل: تقلُّصات المعدة والأمعاء وتشنُّج المثانة البولیة والرّبو وداء الحركة وتقلُّصات عضلیة<br />ومرض الشلل الرعاش وكعامل مساعد في التخدیر).<br />&bull; الأدویة المضادة للتشنّج والأدویة التي تساعد على استقرار المزاج (وھي أدویة تُستخدم في علاج<br />مرض الصرع والاضطرابات ثنائیة القطب مثل: كَرْبامازِیبین أو فینوباربیتال أو فنیتوین أو<br />فوسفینیتوان أو بریمیدون).<br />&bull; كولستیرامین و كولیستیبول (مواد تُستَخدَم بشكل أساسي لعلاج ارتفاع مستویات<br />الدھون في الدَّم).<br />&bull; سیمفاستاتین (دواء یستخدم للتحكم بمستویات الكولیسترول المرتفعة).<br />&bull; سیكلوسبورین (دواء یستخدم في عملیات زراعة الأعضاء لجعل الجسم یتقبل العضو المزروع<br />أو لأغراض أخرى على سبیل المثال: التھاب المفاصل الروماتویدي أو التھاب الجلد التَأَتُّبِيّ).<br />&bull; الأدویة السَّامة للخلایا (والتي تُستَخدَم لعلاج السرطان)، مثل: میثوتریكسات أو سیكلوفوسفامید.<br />&bull; دیجوكسِین أو جلیكوزیدات الدیجیتالس الأخرى (أدویة تُستَخدَم لعلاج مشاكل القلب).<br />&bull; فیرابامیل أو دیلتیازیم (أدویة لعلاج أمراض القلب).<br />&bull; وسائط تباین تحتوي على الیود (أدویة تُستَخدَم في فحوصات التصویر بالأشعة).<br />&bull; أدویة لعلاج مرض السُّكَّرِي (الأدویة الفمویة مثل: میتفورمین أو أنسولین).<br />&bull; أدویة علاج النقرس: ألوبیورینول، أدویة تستخدم لزیادة مستویات السكر في الدم (حاصرات<br />بیتا، دَیازُوكسِید).<br />&bull; الأدویة التي قد تُحفِّز حدوث التواء النقاط (أحد أشكال عدم انتظام دقات القلب البطیني)، مثل<br />مضاد اضطراب النظم القلبي (أدویة تُستَخدَم في علاج مشاكل القلب) وبعض مضادّات الذھان.<br />&bull; الأدویة التي قد تقلِّل كمیة الصودیوم في الدم، مثل: مضادّات الاكتئاب ومضادّات الذھان<br />ومضادّات الصرع.<br />&bull; الأدویة التي قد تقلل كمیة البوتاسیوم في الدم، مثل مدرَّات البول (أقراص الماء) أو<br />الكورتیكوستیرویدات أو المُلیّنات أو أَمْفُوتیریسین أو بنیسللین جي؛<br />&bull; الأدویة التي تُستخدم لرفع ضغط الدَّم، مثل: أدرینالین أو نُورْأَدْرِنالین.<br />&bull; الأدویة المستخدمة لعلاج فیروس نقص المناعة البشري/أو متلازمة نقص المناعة المكتسبة<br />(الإیدز) (على سبیل المثال ریتونافیر وإندینافیر ونیلفینافیر).<br />&bull; الأدویة المستخدمة لعلاج الالتھابات الفطریة (على سبیل المثال كیتوكونازول وإتراكونازول)؛<br />؛( وھي أدویة تُستخدم لعلاج تقرّح والتھاب المريء (كربینوكزولون- ۱<br />&bull; الأدویة التي تستخدم لتخفیف الألم والالتھاب، وخصوصًا مضادّات الالتھاب غیر الستیرویدیة بما<br />؛(۲-Cox في ذلك مثبّطات الأكسدة الحلقیة- ۲ الانتقائیة (مثبطات<br />&bull; الأدویة الباسطة للعضلات (أدویة تعمل على إرخاء العضلات وتستخدم أثناء العملیات):<br />&bull; النتروجلیسرین والنترات الأخرى أو مواد أخرى تسمى &quot;موسّعات الأوعیة&quot;؛<br />&bull; أدویة أخرى تُستخدم لعلاج ارتفاع ضغط الدم، بما في ذلك مثیلدوبا،<br />&bull; ریفامبیسین (دواء یستخدم لعلاج مرض السلّ)، إریثرومیسین، كلاریثرومیسین &quot;من المضادّات<br />الحیویة&quot;<br />&bull; نبتة سانت جونز.<br />&bull; دانترولین (دواء للحقن التسریبي لعلاج اضطرابات درجة حرارة الجسم الشدیدة).<br />&bull; فیتامین &quot;د&quot; وأملاح الكالسیوم.<br />مع الأغذیة والمشروبات والكحولیات &trade; تناوُل فیتوریا إتش سي تي<br />أن یشربوا عصیر جریب فروت أو أن &trade; لا ینبغي للمرضى الذین یتناولون فیتوریا إتش سي تي<br />یأكلوا ثمرة الجریب فروت، وذلك لأن الجریب فروت وعصیر الجریب فروت یمكن أن یؤدي إلى<br />زیادة في مستویات المادة الفعالة أملودیبین في الدم مما قد یسبب زیادة غیر متوقعة؛ وبالتالي یتم<br />تحدّث إلى طبیبك قبل تناول الكحول. حیث قد یؤدي تناول .&trade; تقلیل تأثیر فیتوریا إتش سي تي<br />الكحولیات إلى ھبوط حاد في ضغط الدَّم و/أو زیادة نسبة احتمال الإصابة بالدوخة أو الإغماء.<br />الحمل والرضاعة الطبیعیة<br />الحمل<br />یجب علیكِ إخبار طبیبكِ إذا كنتِ تعتقدین أنكِ حاملاً (أو قد تصبحین) حاملًا. سینصحكِ طبیبك<br />قبل أن تصبحي حاملاً أو بمجرد أن تعلمي أنك &trade; غالبًا بالتوقف عن تناول فیتوریا إتش سي تي<br />لا یُوصى باستخدام فیتوریا .&trade; حامل، سینصحكِ بتناول دواء آخر بدلًا من فیتوریا إتش سي تي<br />في الحمل المبكر ویجب ألا یتم تناوُلھ إذا تجاوز حملك الشھر الثالث حیث إنھ قد &trade; إتش سي تي<br />یُسبب أضرارًا خطیرة لطفلكِ إذا تم استخدامھ بعد الشھر الثالث من الحمل.<br />الرَّضاعة الطبیعیة<br />أخبري طبیبكِ إذا كنتِ تُمارسین الرَّضاعة الطبیعیة، أو على وشك البدء في ممارسة الرَّضاعة<br />الطبیعیة. حیث أثبتت الدراسات أن الأملودیبین یمرّ إلى لبن الأم بكمیات ضئیلة. فلا یُوصي بتناول<br />للأمھات اللواتي یمارسن الرضاعة الطبیعیة وقد یقرر طبیبكِ علاجًا آخر &trade; فیتوریا إتش سي تي<br />إذا كنتِ ترغبین في الرضاعة الطبیعیة، خاصة إذا كان طفلكِ حدیث الولادة أو ولد قبل أوانھ.<br />استشیري طبیبكِ أو الصیدلي الخاص بكِ قبل تناول أي دواء.<br />القیادة واستخدام الآلات<br />قد یسبب لك ھذا الدواء شعورًا بدوخة أو نعاس أو غثیان أو صداع. فإذا شعرت بھذه الأعراض،<br />فعلیك تجنب القیادة واستخدام أیة أدوات أو آلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائمًا ھذا الدَّواء تمامًا كما أخبرك طبیبك. یُرجى مراجعة طبیبك إذا لم تكن متأكدًا من كیفیة<br />التناول. سیساعدك ھذا في الحصول على أفضل النتائج وسیقلّل من خطورة التأثیرات الجانبیة.<br />ھي قرص واحد یومیًّا. &trade; الجرعة المعتادة من فیتوریا إتش سي تي<br />- من الأفضل تناول القرص في الوقت نفسھ من كل یوم ویُنصح بتناولھ في الصباح.<br />- قم بابتلاع الأقراص كاملة مع كوب من الماء.<br />مع &trade; مع الطعام أو بدونھ. لا تتناول فیتوریا إتش سي تي &trade; - یمكنك تناول فیتوریا إتش سي تي<br />ثمرة الجریب فروت أو عصیر جریب فروت.<br />قد یُقرر طبیبك جرعة أعلى أو أقل وفقًا لكیفیة استجابتك للعلاج.<br />لا تتناول كمیة أكثر مما یجب من الجرعات المحددة لك.<br />&trade; إذا تناولت كمیة أكثر مما یجب من فیتوریا إتش سي تي<br />فتحدَّث إلى طبیبك على ،&trade; إذا كنت قد تناولت كمیة كبیرة جدًّا من أقراص فیتوریا إتش سي تي<br />الفور؛ فقد تحتاج إلى عنایة طبیة.<br />&trade; إذا أغفلت تناول جرعة ما من فیتوریا إتش سي تي<br />إذا أغفلت تناول إحدى الجرعات فتناولھا فور تذكرھا، وبعد ذلك قم بتناول الجرعة التالیة في<br />الوقت المحدد لھا. ومع ذلك، إذا قد حان موعد الجُرعة التَّالیة فتجاوَز الجُرعة التي أغفلتھا. ولا<br />تتناول جرعة مضاعفة (قرصین مرة واحدة) لتعویض جرعة أغفلتھا.<br />&trade; إذا توقفت عن تناول فیتوریا إتش سي تي<br />إلى تفاقُم حالتك المرضیة، فلا تتوقَّف عن تناوُل ھذا &trade; قد یُؤدي إیقاف تناول فیتوریا إتش سي تي<br />الدَّواء ما لم یُخبرك طبیبك بذلك.<br />لا تتوقَّف عن تناوُل ھذا الدَّواء، حتى لو شعرت بتحسّن.<br />غالبًا لا یُلاحِظ الأشخاص الذین یعانون من ارتفاع ضغط الدَّم أيّ علامات خاصة بھذه المُشكلة.<br />فقد یشعر الكثیر بأن الأمر طبیعي تمامًا. ومن المھم جدًا تناول دائمًا ھذا الدَّواء تمامًا كما أخبرك<br />طبیبك للحصول على أفضل النتائج والحدّ من خطر الإصابة بأیة تأثیرات جانبیة. حافظ على<br />مواعید متابعتك مع طبیبك حتى إذا كنت تشعر بأنك على ما یُرام. وإذا كانت لدیك أیّة أسئلة إضافیة<br />حول استخدام ھذا الدواء، فاستشر طبیبك أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد یُسبّب ھذا الدواء، مثلھ مثل كافة الأدویة، تأثیرات جانبیة على الرغم من عدم حدوثھا لجمیع<br />المرضى.<br />بالنسبة لأي تركیبة دوائیة مكوّنة من ثلاثة مواد فعاّلة، لا یمكن استبعاد التأثیرات الجانبیة المرتبطة<br />&trade; بكل مكوّن على حدة. حیث تم إدراج التأثیرات الجانبیة الناتجة عن تناول فیتوریا إتش سي تي<br />أو أيّ من المواد الفعالة (أملودیبین وفالسارتان وھیدروكلوروثیازید) فیما یلي والتي قد تحدث مع<br />.&trade; تناول فیتوریا إتش سي تي<br />یمكن أن تكون بعض التأثیرات الجانبیة خطیرة وتحتاج إلى عنایة طبیةً على الفور: استشر<br />طبیبك فورًا إذا شعرت بأيّ من التأثیرات الجانبیة الخطیرة التالیة والنادرة بعد تناول ھذا الدواء:<br />تأثیرات جانبیة شائعة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰ مرضى):<br />&bull; دوخة،<br />&bull; انخفاض ضغط الدم (شعور بالإغماء أو الدُّوار أو فُقدان مفاجئ للوعي).<br />تأثیرات جانبیة غیر شائعة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰۰ مریض):<br />&bull; انخفاض شدید في إخراج البول (انخفاض وظائف الكلى).<br />تأثیرات جانبیة نادرة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰۰۰ مریض):<br />&bull; نزیف تلقائي</p><p>عدم انتظام ضربات القلب<br />&bull; اضطرابات في الكبد<br />تأثیرات جانبیة نادرة جدًّا (قد تُؤثر على ما یصل إلى مریض واحد من بین<br />كل ۱۰٫۰۰۰ مریض)<br />&bull; أزیز مفاجئ، ألم في الصدر، ضیق أو صعوبة التنفس،<br />&bull; تورّم الجفون، الوجھ أو الشفاه،<br />&bull; تورّم اللسان والحلق مما قد یُسبب صعوبة في التنفس.<br />&bull; تفاعلات جلدیة شدیدة تشمل: طفح جلدي شدید، بثور، احمرار جلد الجسم، حكّة شدیدة،<br />تقرحات، تقشّر وتورّم في الجلد، التھاب الأغشیة المخاطیة (متلازمة ستیفنز جونسون، انحلال<br />البشرة النخريّ السمّي) أو تفاعلات حساسة أخرى<br />&bull; نوبة قلبیة، التھاب البنكریاس الذي قد یسبب ألم حاد في البطن والظھر مصحوبًا بشعور<br />بالإعیاء،<br />&bull; ضعف عام، تكدّم، حمى، عدوى متكررة،<br />&bull; تیبّس أو تصلّب.<br />قد تشمل التأثیرات الجانبیة الأخرى ما یلي:<br />تأثیرات جانبیة شائعة جدًّا (قد تُؤثر على أكثر من مریض واحد من بین كل ۱۰ مرضى):<br />&bull; انخفاض مستوى البوتاسیوم في الدَّم.<br />&bull; ارتفاع مستوى الدھون في الدَّم.<br />تأثیرات جانبیة شائعة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰ مرضى):<br />&bull; نُعاس،<br />&bull; حالات خَفَقان القلْب (الإحساس بضربات القلب لدیك)،<br />&bull; احمرار الجلد،<br />&bull; تورُّم الكاحل (وذمة)،<br />&bull; ألم في البطن،<br />&bull; اضطراب المعدة بعد الوجبات،<br />&bull; شعور بالإرھاق،<br />&bull; صداع،<br />&bull; زیادة إدرار البول،<br />&bull; ارتفاع مستوى حَمْض الیوریك في الدَّم،<br />&bull; انخفاض مستوى الماغنسیوم. في الدَّم،<br />&bull; انخفاض مستویات الصودیوم في الدَّم،<br />&bull; شعور بالدوخة، والإغماء عند الوقوف،<br />&bull; انخفاض الشھیة،<br />&bull; غثیان وقيء،<br />&bull; طفح جلدي مصحوب بحكّة وأنواع أخرى من الطفح الجلدي،<br />&bull; عدم القدرة على تحقیق الانتصاب والحفاظ علیھ.</p><p>تأثیرات جانبیة غیر شائعة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰۰ مریض):<br />&bull; سرعة ضربات القلب، &bull; شعور بالدوار، &bull; اضطراب الرؤیة، &bull; اضطراب المعدة،<br />&bull; ألم في الصدر، &bull; زیادة تركیز نیتروجین الیوریا، الكریاتینین وحمض الیوریك في الدم،<br />&bull; ارتفاع مستوى الكالسیوم والدھون في الدَّم، &bull; انخفاض مستوى البوتاسیوم في الدم،<br />&bull; رائحة نَفَس كریھة، &bull; إسھال، &bull; جفاف الفم، &bull; زیادة الوزن، &bull; فقدان الشھیة،<br />&bull; قصور بحاسة التذوق،&bull; ألم في الظھر، &bull; تورّم المفاصل، &bull; تقلّص/ضعف/ألم بالعضلات،<br />&bull; ألم في الأطراف، &bull; عدم القدرة على الوقوف أو المشي بشكل طبیعي، &bull; ضَّعف عام،<br />&bull; اختلال التنسیق الوظیفي، &bull; دوخة عند الوقوف أو بعد ممارسة التمرین،<br />&bull; نقص وفقدان طاقة الجسم (وھن)، &bull; اضطرابات النوم، &bull; تنمیل أو وخز،<br />&bull; اعتلال الأعصاب، &bull; فقدان مفاجئ ومؤقت للوعي، &bull; انخفاض ضغط الدم عند الوقوف،<br />&bull; سعال، &bull; عُسْرُ التَّنَفُّس، &bull; تھیّج الحلق، &bull; تعرّق شدید، &bull; حكّة،<br />&bull; ورم واحمرار وألم في بالأوردة، &bull; احمرار الجلد، &bull; ارتجاف، &bull; تغیّرات في الحالة المزاجیة،<br />&bull; قلق، &bull; اكتئاب، &bull; أرق، &bull; اضطرابات بحاسة التذوق، &bull; إغماء، &bull; فقدان الإحساس بالألم،<br />&bull; اضطرابات الرؤیة، &bull; قصور البصر، &bull; طنین في الأذنین،<br />&bull; عَطْس/سیلان الأنف الناجم عن التھاب الغشاء المبطّن للأنف (التھاب الانف)،<br />&bull; تغیّر حركات الأمعاء، &bull; عسر ھضم، &bull; تساقط الشعر، &bull; حكة بالجلد، &bull; تغیر لون الجلد،<br />&bull; صعوبة في إخراج البول، &bull; زیادة الحاجة إلى التبوّل أثناء اللیل، &bull; زیادة عدد مرات التبوّل،<br />&bull; شعور بعدم الراحة أو تضخم في الثدي لدى الرجال، &bull; الشعور بألم،<br />&bull; شعور بأنك لست على ما یرام، &bull; فقدان الوزن،<br />تأثیرات جانبیة نادرة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰۰۰ مریض):<br />&bull; انخفاض مستوى الصفائح الدَّمویة (المصحوب في بعض الأحیان بنزیف أو تكدُّم تحت الجلد)،<br />&bull; وجود سكر بالبول،<br />&bull; ارتفاع مستوى السُّكر في الدَّم،<br />&bull; تفاقُم الحالة الاستقلابیة (الأیضیّة) لمرض السُّكَّرِي،<br />&bull; اضطراب في البطن،<br />&bull; إمساك،<br />&bull; اضطرابات في الكبد التي قد یصاحبھا اصفرار الجلد والعینین وإخراج بول داكن اللون (فقر<br />الدم الانحلالي)،<br />&bull; زیادة حساسیة الجلد لأشعة الشمس،<br />&bull; ظھور بقع جلدیة حمراء،<br />&bull; اضطرابات الكلى،<br />&bull; الشعور بارتباك<br />تأثیرات جانبیة نادرة جدًّا (قد تُؤثر على ما یصل إلى مریض واحد من بین<br />كل ۱۰,۰۰۰ مریض):<br />&bull; انخفاض عدد كریات الدم البیضاء،<br />&bull; انخفاض مستوى الصفائح الدمویة الذي قد ینتج عنھ كدمات غیر عادیة أو سھولة حدوث نزیف<br />(تلف كریات الدم الحمراء)<br />&bull; تورّم اللثة،<br />&bull; انتفاخ بالبطن (التھاب المعدة)،<br />&bull; التھاب الكبد الوبائي (التھاب الكبد)،<br />&bull; اصفرار الجلد (یرقان)،<br />&bull; زیادة إنزیمات الكبد التي قد تكون لھا تأثیر على بعض الفحوصات الطبیة،<br />&bull; زیادة توتر العضلات،<br />&bull; التھاب الأوعیة الدمویة، غالبًا ما تكون مصحوبة بطفح جلدي،<br />&bull; حساسیة تجاه الضوء،<br />&bull; اضطرابات الجمع بین الشعور بالتیبّس أو التصلّب والرُعشة، و/أو اضطرابات الحركة،<br />&bull; حُمى أو التھاب الحَلْق أو قُرَح الفم بسبب العدوى (أعراض انخفاض مُستوى خلایا الدَّم<br />البیضاء وتُسمى أیضًا بقلة خلایا العَدِلات أو الخلایا المتعادلة).<br />&bull; شحوب لون البشرة، شعور بالإرھاق، ضیق التنفس، إخراج بول داكن (فقر الدَّم الانحلالي)،<br />تكسّر خلایا الدم الحمراء بالأوعیة الدمویة بشكل غیر طبیعي أو بأي موضع آخر بالجسم.<br />&bull; شعور بالارتباك والإرھاق وانتفاض وتقلُّص عضلي، سرعة التنفُّس (انخفاض مستوى<br />الكلورید في الدم)،<br />&bull; ألم شدید في المعدة (التھاب البنكریاس)،<br />&bull; صعوبة في التنفُّس مصحوبة بحُمى، سعال، أزیز بالصدر، عُسْرُ التَّنَفُّس (ضیق التنفس<br />ویشمل: الالتھاب الرئوي والوذمة الرئویة)،<br />&bull; طفح جلدي بالوجھ أو ألم بالمفاصل أو اضطراب بالعضلات أو حُمى (الذئبة الحمامیة)،<br />&bull; التھاب الأوعیة الدَّمویة مصحوبًا بأعراض مثل: طفح جلدي، بُقع حمراء تمیل إلى اللون<br />الأحمر الشدید، حُمى (التھاب الأوعیة الدَّمویة)،<br />&bull; مرض جلدي شدید یُسبب طفحًا جلدیًّا، احمرار الجلد، ظھور بثرات على الشفتین أو العینین أو<br />الفمّ، تقشُّر الجلد، حُمى (انحلال البشرة النخري السمّي)<br />تأثیرات جانبیة غیر معروف معدّل تكرارھا (حیث لا یمكن تقدیر معدل التكرار من واقع البیانات<br />المتاحة):<br />&bull; تغیّرات في فحوصات الدم لوظائف الكُلى، زیادة مستویات البوتاسیوم في الدم، وانخفاض<br />مستوى كریات الدم الحمراء،<br />&bull; ظھور نتائج غیر طبیعیة باختبار كریات الدم الحمراء،<br />&bull; انخفاض مستوى نوع معین من كریات الدم البیضاء والصفائح الدمویة،<br />&bull; زیادة الكریاتینین في الدَّم،<br />&bull; ظھور نتائج غیر طبیعیة باختبار وظائف الكبد،<br />&bull; انخفاض شدید في إدرار البول،<br />&bull; التھاب الأوعیة الدمویة،<br />&bull; ضعف عام، تكدُّم وعدوى مُتكررة (فقر الدَّم اللاتنسجي)،<br />&bull; ضعف الرؤیة وألم بالعینین نتیجة لارتفاع الضغط (علامات مُحتَمَلة للإصابة بزرق العین<br />المصاحب لضیق الزاویة)،<br />&bull; عُسْرُ التَّنَفُّس،<br />&bull; انخفاض شدید في إدرار البول (علامات مُحتَمَلة للإصابة باضطراب أو فشل كُلوي)،<br />&bull; مرض جلدي شدید یُسبب طفحًا جلدیًّا أو احمرار الجلد أو ظھور بثرات على الشفتین أو العینین<br />أو الفم أو تقشُّر الجلد أو حُمى (حُمامَى عَدیدَةُ الأَشْكال)،<br />&bull; تقلصات بالعضلات،<br />&bull; حمى (حرارة وسخونة)،<br />&bull; ظھور بثرات على الجلد وتقرّحھ (وھي علامة للإصابة بالتھاب الجلد الفقاعي)<br />الإبلاغ عن التأثیرات الجانبیة<br />إذا أُصِبت بأیَّة آثار جانبیة، تحدَّث إلى طبیبك أو الصیدلي. بما في ذلك أیّة تأثیرات جانبیة مُحتمَلة<br />غیر مُدرجة في ھذه النَّشرة. ومن خلال قیامك بالإبلاغ عن التأثیرات الجانبیة، یمكنك المساعدة<br />في توفیر معلومات إضافیة حول أمان استخدام ھذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یُحفظ بعیدًا عن متناول و مرأى الأطفال.<br />&bull; لا تستخدم ھذا الدَّواء بعد تاریخ انتھاء الصلاحیة المدوّن على العبوة والشریط بعد كلمة<br />.&quot;EXP&quot;<br />&bull; یُحفظ في درجة حرارة لا تزید عن ۳۰ درجة مئویة.<br />&bull; یُحفظ في العبوة الأصلیة من أجل الحمایة من الرطوبة.<br />&bull; لا تستخدم أي عبوة تالفة أو تظھر علیھا علامات عبث.<br />&bull; لا تقم بالتخلّص من الأدویة عن طریق إلقائھا في میاه الصرف أو مع المخلّفات المنزلیة.<br />واستشر الصیدلي الخاص بك عن كیفیة التَّخلص من الأدویة التي لم تعد بحاجة إلیھا. حیث<br />تُساعد ھذه التدابیر في الحفاظ على البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>على ماذا یحتوي فیتوریا إتش سي تي<br />ھي أملودیبین (على ھیئة أملودیبین بسیلیت) و فالسارتان و &trade; المواد الفعّالة لفیتوریا إتش سي تي<br />ھیدروكلوروثیازید.<br />۲٥ ملجم أقراص مُغلَّفة: /۱٦۰/۱۰ &trade; فیتوریا إتش سي تي<br />یحتوي كل قرص مغلّف على ۱۰ ملجم من أملودیبین في شكل أملودیبین بسیلیت، ۱٦۰ ملجم من<br />فالسارتان و ۲٥ ملجم من ھیدروكلوروثیازید.<br />۲٥ ملجم أقراص مُغلَّفة: /۱٦۰/٥ &trade; فیتوریا إتش سي تي<br />یحتوي كل قرص مغلّف على ٥ ملجم من أملودیبین في شكل أملودیبین بسیلیت، ۱٦۰ ملجم من<br />فالسارتان و ۲٥ ملجم من ھیدروكلوروثیازید.<br />۱۲٫٥ ملجم أقراص مُغلَّفة: /۱٦۰/٥ &trade; فیتوریا إتش سي تي<br />یحتوي كل قرص مغلّف على ٥ ملجم من أملودیبین في شكل أملودیبین بسیلیت، ۱٦۰ ملجم من<br />فالسارتان و ۱۲٫٥ ملجم من ھیدروكلوروثیازید.<br />المكوّنات الأخرى ھي:<br />۲٥ ملجم أقراص مُغلَّفة: /۱٦۰/۱۰ &trade; فیتوریا إتش سي تي<br />سلیلوز دقیق التبلور، كروسبوفیدون، ثاني أكسید السلیكون الغروي، سترات الماغنسیوم،<br />ھیبرومیلوز ، أكسید الحدید الأصفر ، ماكروجال ، ثاني أكسید التیتانیوم ، تلك و لون الغروب<br />الأصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>٥ ملجم أقراص مُغلَّفة: /۱٦۰/٥ &trade; فیتوریا إتش سي تي<br />سلیلوز دقیق التبلور، كروسبوفیدون، ثاني أكسید السلیكون الغروي، سترات الماغنسیوم،<br />ھیبرومیلوز ، أكسید الحدید الأصفر ، ماكروجال ، ثاني أكسید التیتانیوم ، تلك و لون الغروب<br />الأصفر.<br />۱۲٫٥ ملجم أقراص مُغلَّفة: /۱٦۰/٥ &trade; فیتوریا إتش سي تي<br />سلیلوز دقیق التبلور، كروسبوفیدون، ثاني أكسید السلیكون الغروي، سترات الماغنسیوم ،<br />ھیبرومیلوز ، ثاني أكسید التیتانیوم ، ماكروجال و تلك.<br />وما ھي محتویات العبوة؟ ؟&trade; ما ھو شكل فیتوریا إتش سي تي<br />۲٥ ملجم أقراص مُغلَّفة: /۱٦۰/۱۰ &trade; فیتوریا إتش سي تي<br />&quot; شكل أقراص مغلفة ثنائیة التحدُّب بیضاویة الشكل لونھا أصفر، محفور على أحد جانبیھا &quot; 158<br />.&lsquo;JP&rsquo; وعلى الجانب الآخر<br />۲٥ ملجم أقراص مُغلَّفة: /۱٦۰/٥ &trade; فیتوریا إتش سي تي<br />&quot; أقراص مغلفة ثنائیة التحدُّب بیضاویة الشكل لونھا بني أصفر، محفور على أحد جانبیھا &quot; 157<br />.&lsquo;JP&rsquo; وعلى الجانب الآخر<br />۱۲٫٥ ملجم أقراص مُغلَّفة: /۱٦۰/٥ &trade; فیتوریا إتش سي تي<br />أقراص مغلفة ثنائیة التحدُّب بیضاویة الشكل لونھا أبیض إلى مائل للأبیض، محفور على أحد<br />.&lsquo;JP&rsquo; جانبیھا &quot; 156 &quot; وعلى الجانب الآخر<br />في العبوات التالیة: &trade; تتوفر أقراص فیتوریا إتش سي تي<br />۲٥ ملجم علبة تحتوي على ٤ شرائط في كل شریط ۷ أقراص. /۱٦۰/۱۰<br />۲٥ ملجم علبة تحتوي على ٤ شرائط في كل شریط ۷ أقراص. /۱٦۰/٥<br />۱۲,٥ ملجم علبة تحتوي على ٤ شرائط في كل شریط ۷ أقراص. /۱٦۰/٥<br />قد لا یتم تسویق جمیع العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>شركة مصنع جمجوم للأدوية،</p><p>جدة، المملكة العربية السعودية.</p><p>&nbsp;هاتف: 6081111-12-966+</p><p>&nbsp;فاكس: 6081222-12-966+</p><p>الموقع الإلكتروني www.jamjoompharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10-2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vittoria HCT 5 mg/160 mg/12.5 mg film-coated tablets. Vittoria HCT 5 mg/160 mg/25 mg film-coated tablets. Vittoria HCT 10 mg/160 mg/25 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vittoria HCT 5 mg/160 mg/12.5 mg Film-Coated Tablets
Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and
12.5 mg of hydrochlorothiazide.
Vittoria HCT 5 mg/160 mg/25 mg Film-Coated Tablets
Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 25 mg of hydrochlorothiazide.
Vittoria HCT 10 mg/160 mg/25 mg Film-Coated Tablets
Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 25 mg of hydrochlorothiazide.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet

Product	Description for Exhibit Batches	Description for commercial batches
Vittoria	HCT 5/160/12.5 mg Film Coated Tablets	White to off white colored, ovaloid, biconvex film coated tablets debossed with '158' on one side and
'JP' on the other side.	White to off white colored, ovaloid, biconvex film coated tablets debossed with '156' on one side and 'JP' on the
other side.
Vittoria	HCT 5/160/25 mg Film Coated Tablets	Brown yellow colored, ovaloid, biconvex film coated tablets debossed with '158' on one side and
'JP' on the other side.	Brown yellow colored, ovaloid, biconvex film coated tablets debossed with '157' on one side and 'JP' on the
other side.
Vittoria	HCT 10/160/25 mg Film Coated Tablets	Yellow colored, ovaloid, biconvex film coated tablets, debossed with '158' on one side and 'JP' on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.5pt; margin-right:11.35pt; text-align:justify">Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">The recommended dose of Vittoria HCT is one tablet per day, to be taken preferably in the morning. Before switching to Vittoria HCT patients should be controlled on stable doses of the monocomponents taken at the same time. The dose of Vittoria HCT should be based on the doses of the individual components of the combination at the time of switching. The maximum recommended dose of Vittoria HCT is 10 mg/320 mg/25 mg.</p><p style="text-align:justify"><u>Special populations</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify"><em>Renal impairment </em>Due to the hydrochlorothiazide component, Vittoria HCT is contraindicated for use in patients with anuria (see section 4.3) and in patients with severe renal impairment (glomerular filtration rate (GFR) &lt;30 ml/min/1.73 m2) (see sections 4.3, 4.4 and 5.2).</p><p style="margin-left:5.5pt; margin-right:11.35pt; text-align:justify; text-indent:3.0pt">No adjustment of the initial dose is required for patients with mild to moderate renal impairment (see sections 4.4 and 5.2).</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify"><em>Hepatic impairment </em>Due to the valsartan component, Vittoria HCT is contraindicated in patients with severe hepatic impairment (see section 4.3). In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan and therefore Vittoria HCT is not suitable in this group of patients (see sections 4.3, 4.4 and 5.2). Amlodipine dose recommendations have not been established in patients with mild to moderate hepatic impairment. When switching eligible hypertensive patients (see section 4.1) with hepatic impairment to Vittoria HCT, the lowest available dose of the amlodipine component should be used.</p><p style="margin-left:5.5pt; margin-right:11.35pt; text-align:justify"><em>Heart failure </em>and coronary artery disease there is limited experience with the use of Vittoria HCT, particulary at the maximum dose, in patients with heart failure and coronary artery disease. Caution is</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.35pt; text-align:justify">advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Vittoria HCT, 10 mg/320 mg/25 mg.</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify"><em>Elderly </em>(age 65 years or over) Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients, particularly at the maximum dose of Vittoria HCT, 10 mg/320 mg/25 mg, since available data in this patient population are limited. When switching eligible elderly hypertensive patients (see section 4.1) to Vittoria HCT, the lowest available dose of the amlodipine component should be used.</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify"><em>Paediatric population </em>there is no relevant use of Vittoria HCT in the paediatric population (patients below age 18 years) for the indication of essential hypertension.</p><p style="text-align:justify"><u>Method of administration</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:10.5pt">Oral use. Vittoria HCT can be taken with or without food. The tablets should be swallowed whole with some water, at the same time of the day and preferably in the morning.</p><p style="margin-left:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to other sulphonamide derivatives, to dihydropyridine derivatives, or to any of the excipients listed in section 6.1.
□	Second and third trimesters of pregnancy (see sections 4.4 and 4.6).

□	Hepatic impairment, biliary cirrhosis or cholestasis.

□	Severe renal impairment (GFR <30 ml/min/1.73 m2), anuria and patients undergoing dialysis.

□	Concomitant use of Vittoria HCT with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
□	Refractory hypokalaemia, hyponatraemia, hypercalcaemia, and symptomatic hyperuricaemia.

□	Severe hypotension.

□	Shock (including cardiogenic shock).

□	Obstruction of the outflow tract of the left ventricle (e.g. hypertrophic obstructive cardiomyopathy and high grade aortic stenosis).
□	Haemodynamically unstable heart failure after acute myocardial infarction.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:103.65pt">The safety and efficacy of amlodipine in hypertensive crisis have not been established. <u>Sodium- and/or volume-depleted patients</u></p><p style="margin-right:11.3pt; text-align:justify">Excessive hypotension, including orthostatic hypotension, was seen in 1.7% of patients treated with the maximum dose of Vittoria HCT (10 mg/320 mg/25 mg) compared to 1.8% of valsartan/hydrochlorothiazide (320 mg/25 mg) patients, 0.4% of amlodipine/valsartan (10 mg/320 mg) patients, and 0.2% of hydrochlorothiazide/amlodipine (25 mg/10 mg) patients in a controlled trial in patients with moderate to severe uncomplicated hypertension.</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">In sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur after initiation of treatment with Vittoria HCT. Vittoria HCT should be used only after correction of any pre-existing sodium and/or volume depletion.</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">If excessive hypotension occurs with Vittoria HCT, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. Treatment can be continued once blood pressure has been stabilised.</p><p style="margin-left:5.5pt; margin-right:0in; text-align:justify"><strong>Serum electrolyte changes</strong></p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p style="margin-right:11.25pt; text-align:justify"><u>Amlodipine/valsartan/hydrochlorothiazide</u> In the controlled trial of Vittoria HCT, the counteracting effects of valsartan 320 mg and hydrochlorothiazide 25 mg on serum potassium approximately balanced each other in many patients. In other patients, one or the other effect may be dominant. Periodic determinations of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">Periodic determination of serum electrolytes and potassium in particular should be performed at appropriate intervals to detect possible electrolyte imbalance, especially in patients with other risk factors such as impaired renal function, treatment with other medicinal products or history of prior electrolyte imbalances.</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify"><u>Valsartan</u> Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other medicinal products that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify"><u>Hydrochlorothiazide</u> Treatment with Vittoria HCT should only start after correction of hypokalaemia and any coexisting hypomagnesaemia. Thiazide diuretics can precipitate new onset hypokalaemia or exacerbate preexisting hypokalaemia. Thiazide diuretics should be administered with caution in patients with conditions involving enhanced potassium loss, for example salt-losing nephropathies and prerenal (cardiogenic) impairment of kidney function. If hypokalaemia develops during hydrochlorothiazide therapy, Vittoria HCT should be discontinued until stable correction of the potassium balance.</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">Thiazide diuretics can precipitate new onset hyponatraemia and hypochloroaemic alkalosis or exacerbate pre-existing hyponatraemia. Hyponatraemia, accompanied by neurological symptoms (nausea, progressive disorientation, apathy) has been observed. Treatment with hydrochlorothiazide should only be started after correction of pre-existing hyponatraemia. In case severe or rapid hyponatraemia develops during Vittoria HCT therapy, the treatment should be discontinued until normalisation of natraemia.</p><p style="margin-left:5.5pt; margin-right:11.4pt; text-align:justify">All patients receiving thiazide diuretics should be periodically monitored for imbalances in electrolytes, particularly potassium, sodium and magnesium.</p><p style="text-align:justify"><u>Renal impairment</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Thiazide diuretics may precipitate azotaemia in patients with chronic kidney disease. When Vittoria HCT is used in patients with renal impairment periodic monitoring of serum electrolytes (including&nbsp; potassium), creatinine and uric acid serum levels is recommended. Vittoria HCT is contraindicated in patients with severe renal impairment, anuria or undergoing dialysis (see section 4.3).</p><p style="text-align:justify">No dose adjustment of Vittoria HCT is required for patients with mild to moderate renal impairment</p><p style="text-align:justify">(GFR &ge;30 ml/min/1.73 m2).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="text-align:justify"><u>Renal artery stenosis</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">Vittoria HCT should be used with caution to treat hypertension in patients with unilateral or bilateral renal artery stenosis or stenosis to a solitary kidney since blood urea and serum creatinine may increase in such patients.</p><p style="text-align:justify"><u>Kidney transplantation</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>To date there is no experience of the safe use of Vittoria HCT in patients who have had a recent kidney transplantation.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><u>Hepatic impairment</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Valsartan is mostly eliminated unchanged via the bile. The half-life of amlodipine is prolonged and AUC values are higher in patients with impaired liver function; dose recommendations have not been established. In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan, and therefore, Vittoria HCT is not suitable in this group of patients (see sections 4.2, 4.3 and 5.2).</p><p><u>Angioedema</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue, has been reported in patients treated with valsartan. Some of these patients previously experienced angioedema with other medicinal products including ACE inhibitors. Vittoria HCT should be discontinued immediately in patients who develop angioedema and should not be re-administered.</p><p style="text-align:justify"><u>Heart failure and coronary artery disease/post-myocardial infarction</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">As a consequence of the inhibition of the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with ACE inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotaemia and (rarely) with acute renal failure and/or death. Similar outcomes have been reported with valsartan. Evaluation of patients with heart failure or post-myocardial infarction should always include assessment of renal function.</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">In a long-term, placebo-controlled study (PRAISE-2) of amlodipine in patients with NYHA (New York Heart Association Classification) III and IV heart failure of non-ischaemic aetiology, amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo.</p><p style="margin-left:5.5pt; margin-right:11.4pt; text-align:justify">Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Vittoria HCT, 10 mg/320 mg/25 mg, since available data in these patient populations is limited.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><u>Aortic and mitral valve stenosis</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:10.5pt">As with all other vasodilators, special caution is indicated in patients with mitral stenosis or significant aortic stenosis that is not high grade.</p><p><u>Pregnancy</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6)</p><p style="text-align:justify"><u>Primary hyperaldosteronism</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">Patients with primary hyperaldosteronism should not be treated with the angiotensin II antagonist valsartan as their renin-angiotensin system is not activated. Therefore, Vittoria HCT is not recommended in this population.</p><p style="text-align:justify"><u>Systemic lupus erythematosus</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Thiazide diuretics, including hydrochlorothiazide, have been reported to exacerbate or activate systemic lupus erythematosus.</p><p><u>Other metabolic disturbances</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Thiazide diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise serum levels of cholesterol, triglycerides and uric acid. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required.</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Due to the hydrochlorothiazide component, Vittoria HCT is contraindicated in symptomatic hyperuricaemia. Hydrochlorothiazide may raise the serum uric acid level due to reduced clearance of uric acid and may cause or exacerbate hyperuricaemia as well as precipitate gout in susceptible patients.</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">Thiazides reduce urinary calcium excretion and may cause intermittant and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Vittoria HCT is contraindicated in patients with hypercalcaemia and should only be used after correction of any pre-existing hypercalcaemia. Vittoria HCT should be discontinued if hypercalcaemia develops during treatment.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Serum levels of calcium should be periodically monitored during treatment with thiazides. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.</p><p><u>Photosensitivity</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">Cases of photosensitivity reactions have been reported with thiazide diuretics (see section 4.8). If photosensitivity reaction occurs during treatment with Vittoria HCT, it is recommended to stop the treatment. If a readministration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.</p><p style="text-align:justify"><u>Acute angle-closure glaucoma</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.35pt; text-align:justify">Hydrochlorothiazide, a sulphonamide, has been associated with an idiosyncratic reaction resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to a week of treatment initiation. Untreated acute-angle closure glaucoma can lead to permanent vision loss.</p><p style="margin-left:5.5pt; margin-right:11.35pt; text-align:justify">The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatment may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle closure glaucoma may include a history of sulphonamide or penicillin allergy.</p><p><u>General</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Caution should be exercised in patients who have shown prior hypersensitivity to other angiotensin II receptor antagonists. Hypersensitivity reactions to hydrochlorothiazide are more likely in patients with allergy and asthma.</p><p style="text-align:justify"><u>Elderly (age 65 years or over)</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients, particularly at the maximum dose of Vittoria HCT, 10 mg/320 mg/25 mg, since available data in this patient population are limited.</p><p style="text-align:justify"><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">There is evidence that the concomitant use of ACE inhibitors, ARBs or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE inhibitors, ARBs or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p style="margin-left:5.5pt; margin-right:11.35pt; text-align:justify">If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE inhibitors and ARBs should not be used concomitantly in patients with diabetic nephropathy.</p><p style="text-align:justify"><u>Non-melanoma skin cancer</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)] with increasing cumulative dose of hydrochlorothiazide exposure has been observed in two epidemiological studies based on the Danish National Cancer Registry. Photosensitising actions of hydrochlorothiazide could act as a possible mechanism for NMSC.</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Patients taking hydrochlorothiazide should be informed of the risk of NMSC and advised to regularly check their skin for any new lesions and promptly report any suspicious skin lesions. Possible preventive measures such as limited exposure to sunlight and UV rays and, in case of exposure, adequate protection should be advised to the patients in order to minimise the risk of skin cancer. Suspicious skin lesions should be promptly examined potentially including histological examinations of biopsies. The use of hydrochlorothiazide may also need to be reconsidered in patients who have experienced previous NMSC (see also section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">No formal interaction studies with other medicinal products have been performed with Vittoria HCT. Thus, only information on interactions with other medicinal products that are known for the individual active substances is provided in this section.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:11.35pt; text-align:justify">However, it is important to take into account that Vittoria HCT may increase the hypotensive effect of other antihypertensive agents.</p><p style="text-align:justify"><u>Concomitant use not recommended</u></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#5b9bd5; height:31.7pt; vertical-align:top; width:144.9pt"><p style="margin-left:2.35pt; margin-right:14.8pt; text-align:center"><strong>Vittoria HCT individual</strong></p><p style="margin-left:2.35pt; margin-right:14.75pt; text-align:center"><strong>component</strong></p></td><td style="height:31.7pt; vertical-align:top; width:171.0pt"><p style="margin-left:.65pt; margin-right:13.15pt; text-align:center"><strong>Known interactions with the</strong></p><p style="margin-left:.65pt; margin-right:13.0pt; text-align:center"><strong>following agents</strong></p></td><td style="height:31.7pt; vertical-align:top; width:189.9pt"><p style="margin-left:-.7pt; margin-right:11.8pt; text-align:center"><strong>Effect of the interaction with other</strong></p><p style="margin-left:13.95pt; margin-right:26.3pt; text-align:center"><strong>medicinal products</strong></p></td></tr><tr><td style="background-color:#d6e6f4; border-color:#5b9bd5; height:31.75pt; width:144.9pt"><p style="margin-left:14.65pt; margin-right:0in"><strong>Valsartan and HCT</strong></p></td><td style="background-color:#d6e6f4; height:31.75pt; width:171.0pt"><p style="margin-left:.65pt; margin-right:13.1pt; text-align:center">Lithium</p></td><td style="background-color:#d6e6f4; height:31.75pt; width:189.9pt"><p style="margin-left:13.95pt; margin-right:4.95pt; text-align:center">Reversible increases in serum</p><p style="margin-left:13.9pt; margin-right:4.85pt; text-align:center">lithium concentrations and toxicity</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="background-color:#d6e6f4; border-color:#5b9bd5; height:206.25pt; width:144.9pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; border-color:#5b9bd5; height:206.25pt; width:171.0pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; border-color:#5b9bd5; height:206.25pt; width:189.9pt"><p style="margin-left:13.95pt; margin-right:4.85pt; text-align:center">have been reported during concomitant administration of lithium with ACE inhibitors, angiotensin II receptor antagonists including valsartan or thiazides.</p><p style="margin-left:13.95pt; margin-right:4.85pt; text-align:center">Since renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity may presumably be increased further with Vittoria HCT. Therefore careful monitoring of serum lithium concentrations is recommended during concomitant</p><p style="margin-left:13.95pt; margin-right:4.95pt; text-align:center">use.</p></td></tr><tr><td style="border-color:#5b9bd5; height:79.3pt; vertical-align:top; width:144.9pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:40.35pt"><strong>Valsartan</strong></p></td><td style="height:79.3pt; vertical-align:top; width:171.0pt"><p style="margin-left:.65pt; margin-right:13.2pt; text-align:center">Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may</p><p style="margin-left:.65pt; margin-right:13.1pt; text-align:center">increase potassium levels</p></td><td style="height:79.3pt; vertical-align:top; width:189.9pt"><p style="margin-left:13.9pt; margin-right:4.85pt; text-align:center">If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, frequent monitoring of</p><p style="margin-left:12.8pt; margin-right:3.7pt; text-align:center">potassium plasma levels is advised.</p></td></tr><tr><td style="background-color:#d6e6f4; border-color:#5b9bd5; height:95.2pt; width:144.9pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:53.65pt; margin-right:0in"><strong>Amlodipine</strong></p></td><td style="background-color:#d6e6f4; height:95.2pt; width:171.0pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:8.9pt; margin-right:0in">Grapefruit or grapefruit juice</p></td><td style="background-color:#d6e6f4; height:95.2pt; width:189.9pt"><p style="margin-left:13.95pt; margin-right:4.85pt; text-align:center">Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood</p><p style="margin-left:13.95pt; margin-right:4.9pt; text-align:center">pressure lowering effects.</p></td></tr></tbody></table><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:0in"><u>Caution required with concomitant use</u></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#5b9bd5; height:31.75pt; vertical-align:top; width:167.5pt"><p style="margin-left:13.65pt; margin-right:26.15pt; text-align:center"><strong>Vittoria HCT individual</strong></p><p style="margin-left:13.65pt; margin-right:26.1pt; text-align:center"><strong>component</strong></p></td><td style="height:31.75pt; vertical-align:top; width:168.65pt"><p style="margin-left:.05pt; margin-right:12.45pt; text-align:center"><strong>Known interactions with the</strong></p><p style="margin-left:.2pt; margin-right:12.45pt; text-align:center"><strong>following agents</strong></p></td><td style="height:31.75pt; vertical-align:top; width:169.6pt"><p style="margin-left:.05pt; margin-right:12.4pt; text-align:center"><strong>Effect of the interaction with</strong></p><p style="margin-left:.1pt; margin-right:12.4pt; text-align:center"><strong>other medicinal products</strong></p></td></tr><tr><td style="background-color:#d6e6f4; border-color:#5b9bd5; height:158.7pt; width:167.5pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:46.95pt; margin-right:0in"><strong>Amlodipine</strong></p></td><td style="background-color:#d6e6f4; height:158.7pt; width:168.65pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:12.1pt; margin-right:24.4pt; text-align:center; text-indent:-.1pt">CYP3A4 inhibitors (i.e. ketoconazole, itraconazole, ritonavir</p></td><td style="background-color:#d6e6f4; height:158.7pt; width:169.6pt"><p style="margin-left:7.6pt; margin-right:6.6pt; text-align:center; text-indent:.05pt">Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The</p><p style="margin-left:3.45pt; margin-right:2.5pt; text-align:center">clinical translation of these</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="32" style="background-color:#d6e6f4; border-color:#5b9bd5; height:14.6pt; width:167.5pt"><p>&nbsp;</p></td><td rowspan="5" style="background-color:#d6e6f4; border-color:#5b9bd5; height:14.6pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.6pt; width:169.6pt"><p style="margin-right:6.7pt; text-align:right">pharmacokinetic variations may</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:20.45pt; margin-right:0in">be more pronounced in the</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:0in; margin-right:6.65pt; text-align:right">elderly. Clinical monitoring and</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:15.45pt; margin-right:0in">dose adjustment may thus be</p></td></tr><tr><td style="background-color:#d6e6f4; height:16.1pt; width:169.6pt"><p style="margin-left:3.45pt; margin-right:2.45pt; text-align:center">required.</p></td></tr><tr><td style="height:14.6pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.6pt; vertical-align:top; width:169.6pt"><p style="margin-left:21.1pt; margin-right:0in">Upon co-administration of</p></td></tr><tr><td style="height:14.8pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.8pt; vertical-align:top; width:169.6pt"><p style="margin-left:0in; margin-right:5.2pt; text-align:right">known inducers of the CYP3A4,</p></td></tr><tr><td style="height:125.95pt; vertical-align:top; width:168.65pt"><p style="margin-left:10.85pt; margin-right:9.75pt; text-align:center; text-indent:.05pt">CYP3A4 inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone], rifampicin, Hypericum perforatum [St.</p><p style="margin-left:3.75pt; margin-right:2.75pt; text-align:center">John&rsquo;s wort])</p></td><td style="height:125.95pt; vertical-align:top; width:169.6pt"><p style="margin-left:5.6pt; margin-right:4.5pt; text-align:center; text-indent:-.05pt">the plasma concentration of amlodipine may vary. Therefore, blood pressure should be monitored and dose regulation considered both during and after concomitant medication particularly with strong</p><p style="margin-left:3.45pt; margin-right:2.45pt; text-align:center">CYP3A4 inducers (e.g.</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:31.1pt; margin-right:0in">rifampicin, hypericum</p></td></tr><tr><td style="height:16.05pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:16.05pt; vertical-align:top; width:169.6pt"><p style="margin-left:54.65pt; margin-right:0in">perforatum).</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.6pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.6pt; width:169.6pt"><p style="margin-left:13.05pt; margin-right:0in">Co-administration of multiple</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:0in; margin-right:6.5pt; text-align:right">doses of 10 mg amlodipine with</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:0in; margin-right:8.9pt; text-align:right">80 mg simvastatin resulted in a</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:17.1pt; margin-right:0in">77% increase in exposure to</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p style="margin-left:.15pt; margin-right:12.45pt; text-align:center">Simvastatin</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:26.15pt; margin-right:0in">simvastatin compared to</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:30.75pt; margin-right:0in">simvastatin alone. It is</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:10.45pt; margin-right:0in">recommended to limit the dose</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:0in; margin-right:7.3pt; text-align:right">of simvastatin to 20 mg daily in</p></td></tr><tr><td style="background-color:#d6e6f4; height:16.05pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:16.05pt; width:169.6pt"><p style="margin-left:28.6pt; margin-right:0in">patients on amlodipine.</p></td></tr><tr><td style="height:14.6pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.6pt; vertical-align:top; width:169.6pt"><p style="margin-left:16.25pt; margin-right:0in">In animals, lethal ventricular</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:12.9pt; margin-right:0in">fibrillation and cardiovascular</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:27.4pt; margin-right:0in">collapse are observed in</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:0in; margin-right:7.55pt; text-align:right">association with hyperkalaemia</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:31.55pt; margin-right:0in">after administration of</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:.3in; margin-right:0in">verapamil and intravenous</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p style="margin-left:.2pt; margin-right:12.45pt; text-align:center">Dantrolene (infusion)</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:23.75pt; margin-right:0in">dantrolene. Due to risk of</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:38.1pt; margin-right:0in">hyperkalaemia, it is</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:22.75pt; margin-right:0in">recommended that the co-</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:23.55pt; margin-right:0in">administration of calcium</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:25.75pt; margin-right:0in">channel blockers such as</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:24.4pt; margin-right:0in">amlodipine be avoided in</p></td></tr><tr><td style="height:16.15pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:16.15pt; vertical-align:top; width:169.6pt"><p style="margin-left:0in; margin-right:4.75pt; text-align:right">patients susceptible to malignant</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="background-color:#d6e6f4; border-color:#5b9bd5; height:47.6pt; width:167.5pt"><p>&nbsp;</p></td><td style="border-color:#5b9bd5; height:47.6pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="border-color:#5b9bd5; height:47.6pt; vertical-align:top; width:169.6pt"><p style="margin-left:22.55pt; text-indent:5.5pt">hyperthermia and in the</p><p style="margin-left:51.75pt; margin-right:19.8pt; text-indent:-29.25pt">management of malignant hyperthermia.</p></td></tr><tr><td style="background-color:#d6e6f4; border-color:#5b9bd5; height:238.0pt; width:167.5pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:13.65pt; margin-right:26.15pt; text-align:center"><strong>Valsartan and HCT</strong></p></td><td style="background-color:#d6e6f4; height:238.0pt; width:168.65pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:3.75pt; margin-right:3.7pt; text-align:center">Non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid (&gt;3 g/day), and nonselective NSAIDs</p></td><td style="background-color:#d6e6f4; height:238.0pt; width:169.6pt"><p style="margin-left:11.75pt; margin-right:9.7pt; text-align:center; text-indent:-.05pt">NSAIDS can attenuate the antihypertensive effect of both angiotensin II antagonists and hydrochlorothiazide when administered simultaneously.</p><p style="margin-left:6.55pt; margin-right:4.55pt; text-align:center">Furthermore, concomitant use of Vittoria HCT and NSAIDs may lead to worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the</p><p style="margin-left:3.45pt; margin-right:1.5pt; text-align:center">patient.</p></td></tr><tr><td style="border-color:#5b9bd5; height:190.4pt; vertical-align:top; width:167.5pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:13.65pt; margin-right:26.05pt; text-align:center"><strong>Valsartan</strong></p></td><td style="height:190.4pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:3.75pt; margin-right:3.7pt; text-align:center">Inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir)</p></td><td style="height:190.4pt; vertical-align:top; width:169.6pt"><p style="margin-left:8.55pt; margin-right:6.55pt; text-align:center">The results of an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and of the hepatic efflux transporter MRP2. Co- administration of inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) may increase the systemic</p><p style="margin-left:3.45pt; margin-right:1.5pt; text-align:center">exposure to valsartan.</p></td></tr><tr><td style="background-color:#d6e6f4; border-color:#5b9bd5; height:142.85pt; width:167.5pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:13.65pt; margin-right:26.05pt; text-align:center"><strong>HCT</strong></p></td><td style="background-color:#d6e6f4; height:142.85pt; width:168.65pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:62.65pt; margin-right:25.25pt; text-indent:-35.55pt">Alcohol, barbiturates or narcotics</p></td><td style="background-color:#d6e6f4; height:142.85pt; width:169.6pt"><p style="margin-left:10.9pt; margin-right:8.55pt; text-align:center; text-indent:-.1pt">Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic</p><p style="margin-left:3.45pt; margin-right:1.3pt; text-align:center">hypotension.</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="30" style="background-color:#d6e6f4; border-color:#5b9bd5; height:14.6pt; width:167.5pt"><p>&nbsp;</p></td><td style="height:14.6pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.6pt; vertical-align:top; width:169.6pt"><p style="margin-left:3.45pt; margin-right:1.3pt; text-align:center">Thiazides, including</p></td></tr><tr><td style="height:30.7pt; vertical-align:top; width:168.65pt"><p style="margin-left:.2pt; margin-right:12.45pt; text-align:center">Amantadine</p></td><td style="height:30.7pt; vertical-align:top; width:169.6pt"><p style="margin-left:23.75pt; margin-right:0in">hydrochlorothiazide, may</p><p style="margin-left:20.1pt; margin-right:0in">increase the risk of adverse</p></td></tr><tr><td style="height:16.05pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:16.05pt; vertical-align:top; width:169.6pt"><p style="margin-left:3.45pt; margin-right:1.25pt; text-align:center">reactions caused by amantadine.</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.65pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.65pt; width:169.6pt"><p style="margin-left:3.45pt; margin-right:1.25pt; text-align:center">The bioavailability of thiazide-</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:3.45pt; margin-right:1.3pt; text-align:center">type diuretics may be increased</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.8pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.8pt; width:169.6pt"><p style="margin-left:3.45pt; margin-right:1.25pt; text-align:center">by anticholinergic agents (e.g.</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:3.45pt; margin-right:1.3pt; text-align:center">atropine, biperiden), apparently</p></td></tr><tr><td style="background-color:#d6e6f4; height:62.45pt; width:168.65pt"><p style="margin-left:-.9pt; margin-right:11.45pt; text-align:center">Anticholinergic agents and other medicinal products affecting gastric motility</p></td><td style="background-color:#d6e6f4; height:62.45pt; width:169.6pt"><p style="margin-left:3.45pt; margin-right:1.2pt; text-align:center">due to a decrease in gastrointestinal motility and the stomach emptying rate.</p><p style="margin-left:3.45pt; margin-right:1.35pt; text-align:center">Conversely, it is anticipated that</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:3.45pt; margin-right:1.3pt; text-align:center">prokinetic substances such as</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:3.45pt; margin-right:1.25pt; text-align:center">cisapride may decrease the</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:3.45pt; margin-right:1.25pt; text-align:center">bioavailability of thiazide-type</p></td></tr><tr><td style="background-color:#d6e6f4; height:16.1pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:16.1pt; width:169.6pt"><p style="margin-left:3.45pt; margin-right:1.15pt; text-align:center">diuretics.</p></td></tr><tr><td style="height:14.6pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.6pt; vertical-align:top; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.75pt; text-align:center">Thiazides may alter glucose</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.8pt; text-align:center">tolerance. Dose adjustment of</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.8pt; text-align:center">the antidiabetic medicinal</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p style="margin-left:.15pt; margin-right:12.45pt; text-align:center">Antidiabetic agents (e.g. insulin</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.8pt; text-align:center">product may be necessary.</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p style="margin-left:.2pt; margin-right:12.45pt; text-align:center">and oral antidiabetic agents)</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.8pt; text-align:center">Metformin should be used with</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p style="margin-left:.15pt; margin-right:12.45pt; text-align:center">Metformin</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.75pt; text-align:center">caution because of the risk of</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.7pt; text-align:center">lactic acidosis induced by</p></td></tr><tr><td style="height:14.85pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:14.85pt; vertical-align:top; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.75pt; text-align:center">possible functional renal failure</p></td></tr><tr><td style="height:16.1pt; vertical-align:top; width:168.65pt"><p>&nbsp;</p></td><td style="height:16.1pt; vertical-align:top; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.65pt; text-align:center">linked to hydrochlorothiazide.</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.6pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.6pt; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.8pt; text-align:center">Concomitant use of thiazide</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.8pt; text-align:center">diuretics, including</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.8pt; text-align:center">hydrochlorothiazide, with beta</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.75pt; text-align:center">blockers may increase the risk</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p style="margin-left:.1pt; margin-right:12.45pt; text-align:center">Beta blockers and diazoxide</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.75pt; text-align:center">of hyperglycaemia. Thiazide</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.8pt; text-align:center">diuretics, including</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.8pt; text-align:center">hydrochlorothiazide, may</p></td></tr><tr><td style="background-color:#d6e6f4; height:14.85pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:14.85pt; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.8pt; text-align:center">enhance the hyperglycaemic</p></td></tr><tr><td style="background-color:#d6e6f4; height:16.1pt; width:168.65pt"><p>&nbsp;</p></td><td style="background-color:#d6e6f4; height:16.1pt; width:169.6pt"><p style="margin-left:8.55pt; margin-right:1.75pt; text-align:center">effect of diazoxide</p></td></tr></tbody></table><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#8eaadb; height:63.45pt; vertical-align:top; width:167.05pt"><p>&nbsp;</p><p style="margin-left:62.8pt; margin-right:75.7pt; text-align:center"><strong>HCT</strong></p></td><td style="height:63.45pt; vertical-align:top; width:168.85pt"><p>&nbsp;</p><p style="margin-left:47.95pt; margin-right:0in"><strong>Ciclosporin</strong></p></td><td style="height:63.45pt; vertical-align:top; width:169.95pt"><p style="margin-left:.15in; margin-right:12.95pt; text-align:justify; text-indent:-.5pt"><strong>Concomitant treatment with ciclosporin may increase the risk of hyperuricaemia and</strong></p><p style="margin-left:20.65pt; margin-right:0in; text-align:justify"><strong>gout-type complications.</strong></p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="5" style="border-color:#8eaadb; height:95.15pt; vertical-align:top; width:167.05pt"><p>&nbsp;</p></td><td style="background-color:#d9e2f3; border-color:#8eaadb; height:95.15pt; width:168.85pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.1pt; margin-right:22.05pt; text-align:center">Cytotoxic agents</p></td><td style="background-color:#d9e2f3; border-color:#8eaadb; height:95.15pt; width:169.95pt"><p style="margin-left:2.15pt; margin-right:4.85pt; text-align:center; text-indent:-.1pt">Thiazides, including hydrochlorothiazide, may reduce the renal excretion of cytotoxic agents (e.g. cyclophosphamide, methotrexate) and potentiate their</p><p style="margin-left:2.4pt; margin-right:5.1pt; text-align:center">myelosuppressive effects.</p></td></tr><tr><td style="height:79.35pt; vertical-align:top; width:168.85pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.15pt; margin-right:22.05pt; text-align:center">Digitalis glycosides</p></td><td style="height:79.35pt; vertical-align:top; width:169.95pt"><p style="margin-left:5.3pt; margin-right:8.0pt; text-align:center; text-indent:-.05pt">Thiazide-induced hypokalaemia or hypomagnesaemia may occur as undesirable effects, favouring the onset of digitalis-induced</p><p style="margin-left:2.45pt; margin-right:5.1pt; text-align:center">cardiac arrhythmias.</p></td></tr><tr><td style="background-color:#d9e2f3; height:111.0pt; width:168.85pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.1pt; margin-right:22.05pt; text-align:center">Iodine contrasting agents</p></td><td style="background-color:#d9e2f3; height:111.0pt; width:169.95pt"><p style="margin-left:2.4pt; margin-right:5.1pt; text-align:center">In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of iodine products. Patients should be re-hydrated before the</p><p style="margin-left:2.45pt; margin-right:5.1pt; text-align:center">administration</p></td></tr><tr><td style="height:253.9pt; vertical-align:top; width:168.85pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.1pt; margin-right:22.05pt; text-align:center">Ion exchange resins</p></td><td style="height:253.9pt; vertical-align:top; width:169.95pt"><p style="margin-left:3.8pt; margin-right:6.55pt; text-align:center">Absorption of thiazide diuretics, including hydrochlorothiazide, is decreased by cholestyramine or colestipol. This could result in sub-therapeutic effects of thiazide diuretics. However, staggering the dosage of hydrochlorothiazide and resin such that hydrochlorothiazide is administered at least 4 hours before or 4-6 hours after the administration of resins would potentially minimise the interaction.</p></td></tr><tr><td style="background-color:#d9e2f3; height:79.35pt; width:168.85pt"><p>&nbsp;</p><p style="margin-left:30.3pt; margin-right:14.1pt; text-indent:-15.7pt">Medicinal products affecting serum potassium level</p></td><td style="background-color:#d9e2f3; height:79.35pt; width:169.95pt"><p style="margin-left:17.6pt; margin-right:17.1pt; text-align:center; text-indent:-.05pt">The hypokalaemic effect of hydrochlorothiazide may be increased by concomitant administration of kaliuretic</p><p style="margin-left:2.85pt; margin-right:2.5pt; text-align:center">diuretics, corticosteroids,</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#8eaadb; height:174.5pt; vertical-align:top; width:167.05pt"><p>&nbsp;</p></td><td style="background-color:#d9e2f3; border-color:#8eaadb; height:174.5pt; width:168.85pt"><p>&nbsp;</p></td><td style="background-color:#d9e2f3; border-color:#8eaadb; height:174.5pt; width:169.95pt"><p style="margin-left:5.55pt; margin-right:5.1pt; text-align:center">laxatives, adrenocorticotropic hormone (ACTH), amphotericin, carbenoxolone, penicillin G and salicylic acid derivatives or antiarrhythmics. If these medicinal products are to be prescribed with the amlodipine</p><p style="margin-left:2.85pt; margin-right:2.35pt; text-align:center">/valsartan /hydrochlorothiazide combination, monitoring of potassium plasma levels is</p><p style="margin-left:2.85pt; margin-right:2.45pt; text-align:center">advised.</p></td></tr><tr><td rowspan="3" style="border-color:#8eaadb; height:142.8pt; vertical-align:top; width:167.05pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:62.8pt; margin-right:75.7pt; text-align:center"><strong>HCT</strong></p></td><td style="height:142.8pt; vertical-align:top; width:168.85pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:37.0pt; margin-right:14.05pt; text-indent:-22.35pt">Medicinal products affecting serum sodium level</p></td><td style="height:142.8pt; vertical-align:top; width:169.95pt"><p style="margin-left:9.35pt; margin-right:8.95pt; text-align:center; text-indent:.05pt">The hyponatraemic effect of diuretics may be intensified by concomitant administration of medicinal products such as antidepressants, antipsychotics, antiepileptics, etc. Caution is indicated in long-term administration of these</p><p style="margin-left:2.85pt; margin-right:2.5pt; text-align:center">medicinal products.</p></td></tr><tr><td style="background-color:#d9e2f3; height:142.8pt; width:168.85pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:6.0pt; margin-right:5.35pt; text-indent:38.9pt">Medicinal products that could induce torsades de pointes</p></td><td style="background-color:#d9e2f3; height:142.8pt; width:169.95pt"><p style="margin-left:3.8pt; margin-right:3.3pt; text-align:center">Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce torsades de pointes, in particular Class Ia and Class III antiarrhythmics and some</p><p style="margin-left:2.85pt; margin-right:2.5pt; text-align:center">antipsychotics.</p></td></tr><tr><td style="height:158.65pt; vertical-align:top; width:168.85pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:8.35pt; margin-right:8.55pt; text-align:justify; text-indent:1.6pt">Medicinal products used in the treatment of gout (probenecid, sulfinpyrazone and allopurinol)</p></td><td style="height:158.65pt; vertical-align:top; width:169.95pt"><p style="margin-left:8.4pt; margin-right:7.9pt; text-align:center">Dose adjustment of uricosuric medicinal products may be necessary as hydrochlorothiazide may raise the level of serum uric acid.</p><p style="margin-left:8.35pt; margin-right:7.9pt; text-align:center; text-indent:.05pt">Increase of dose of probenecid or sulfinpyrazone may be necessary. Co-administration of thiazide diuretics, including</p><p style="margin-left:2.85pt; margin-right:2.55pt; text-align:center">hydrochlorothiazide, may</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="3" style="border-color:#8eaadb; height:47.6pt; vertical-align:top; width:167.05pt"><p>&nbsp;</p></td><td style="border-color:#8eaadb; height:47.6pt; vertical-align:top; width:168.85pt"><p>&nbsp;</p></td><td style="border-color:#8eaadb; height:47.6pt; vertical-align:top; width:169.95pt"><p style="margin-left:2.85pt; margin-right:2.55pt; text-align:center">increase the incidence of</p><p style="margin-left:2.85pt; margin-right:2.4pt; text-align:center">hypersensitivity reactions to allopurinol.</p></td></tr><tr><td style="background-color:#d9e2f3; height:79.25pt; width:168.85pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:55.4pt">Methyldopa</p></td><td style="background-color:#d9e2f3; height:79.25pt; width:169.95pt"><p style="margin-left:5.75pt; margin-right:5.25pt; text-align:center; text-indent:-.05pt">There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and</p><p style="margin-left:2.85pt; margin-right:2.4pt; text-align:center">methyldopa.</p></td></tr><tr><td style="height:47.6pt; vertical-align:top; width:168.85pt"><p style="margin-left:16.35pt; margin-right:15.9pt; text-align:center">Non-depolarising skeletal muscle relaxants (e.g.</p><p style="margin-left:16.35pt; margin-right:15.95pt; text-align:center">tubocurarine)</p></td><td style="height:47.6pt; vertical-align:top; width:169.95pt"><p style="margin-left:10.65pt; margin-right:8.65pt; text-align:center; text-indent:.05pt">Thiazides, including hydrochlorothiazide, potentiate</p><p style="margin-left:2.85pt; margin-right:.85pt; text-align:center">the action of curare derivatives.</p></td></tr><tr><td rowspan="3" style="background-color:#d9e2f3; border-color:#8eaadb; height:126.9pt; width:167.05pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:62.8pt; margin-right:75.7pt; text-align:center"><strong>HCT</strong></p></td><td style="background-color:#d9e2f3; height:126.9pt; width:168.85pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:38.55pt; margin-right:26.2pt; text-indent:-11.05pt">Other anti-hypertensive medicinal products</p></td><td style="background-color:#d9e2f3; height:126.9pt; width:169.95pt"><p style="margin-left:.1in; margin-right:5.1pt; text-align:center">Thiazides potentiate the antihypertensive action of other antihypertensive drugs (e.g. guanethidine, methyldopa, beta- blockers, vasodilators, calcium channel blockers, ACE inhibitors, ARBs and Direct</p><p style="margin-left:2.85pt; margin-right:.9pt; text-align:center">Renin Inhibitors [DRIs]).</p></td></tr><tr><td style="height:95.15pt; vertical-align:top; width:168.85pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:21.35pt; margin-right:20.05pt; text-indent:14.6pt">Pressor amines (e.g. noradrenaline, adrenaline)</p></td><td style="height:95.15pt; vertical-align:top; width:169.95pt"><p style="margin-left:10.0pt; margin-right:7.95pt; text-align:center; text-indent:-.1pt">Hydrochlorothiazide may reduce the response to pressor amines such as noradrenaline. The clinical significance of this effect is uncertain and not</p><p style="margin-left:2.85pt; margin-right:.9pt; text-align:center">sufficient to preclude their use.</p></td></tr><tr><td style="background-color:#d9e2f3; height:222.2pt; width:168.85pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.25pt; margin-right:0in">Vitamin D and calcium salts</p></td><td style="background-color:#d9e2f3; height:222.2pt; width:169.95pt"><p style="margin-left:7.35pt; margin-right:5.35pt; text-align:center; text-indent:-.05pt">Administration of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with calcium salts may potentiate the rise in serum calcium. Concomitant use of thiazide type diuretics may lead to hypercalcaemia in patients pre-disposed for hypercalcaemia (e.g. hyperparathyroidism, malignancy or vitamin-D- mediated conditions) by increasing tubular calcium</p><p style="margin-left:2.85pt; margin-right:.9pt; text-align:center">reabsorption.</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="text-align:justify"><u>Dual blockade of the RAAS with ARBs, ACE inhibitors or aliskiren</u></p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Clinical trial data have shown that dual blockade of the RAAS through the combined use of ACE inhibitors, ARBs or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if !supportLists]-->1.1&nbsp;&nbsp; <!--[endif]-->Pregnancy</p><p style="margin-right:11.4pt; text-align:justify"><u>Amlodipine</u> The safety of amlodipine in human pregnancy has not been established. In animal studies, reproductive toxicity was observed at high doses (see section 5.3). Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify"><u>Valsartan</u> The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.25pt; text-align:justify">Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and if appropriate, alternative therapy should be started.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.35pt; text-align:justify">Exposure to AIIRAs therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).</p><p style="margin-right:11.3pt; text-align:justify">Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.35pt; text-align:justify">Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.4pt; text-align:justify"><u>Hydrochlorothiazide</u> There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient.</p><p style="margin-right:11.25pt; text-align:justify">Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide, its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify"><u>Amlodipine/valsartan/hydrochlorothiazide</u> there is no experience on the use of Vittoria HCT in pregnant women. Based on the existing data with the components, the use of Vittoria HCT is not recommended during first trimester and contraindicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><u>Breast-feeding</u></p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">Amlodipine is excreted in human milk. The proportion of the maternal dose received by the infant has been estimated with an interquartile range of 3-7%, with a maximum of 15%. The effect of amlodipine on infants is unknown. No information is available regarding the use of valsartan during breast-feeding. Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit milk production. The use of Vittoria HCT during breastfeeding is not recommended. If Vittoria HCT is used during breast-feeding, doses should be kept as low as possible. Alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p style="text-align:justify"><u>Fertility </u></p><p style="margin-left:5.5pt; margin-right:235.05pt">There are no clinical studies on fertility with Vittoria HCT. <u>Valsartan</u></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.35pt; text-align:justify">Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is 6 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).</p><p><u>Amlodipine</u></p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Patients taking Vittoria HCT and driving vehicles or using machines should take into account that dizziness or weariness may occasionally occur.</p><p style="margin-right:11.3pt; text-align:justify">Amlodipine can have mild or moderate influence on the ability to drive and use machines. If patients taking Vittoria HCT suffer from dizziness, headache, fatigue or nausea the ability to react may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">The safety profile of Vittoria HCT presented below is based on clinical studies performed with Vittoria HCT and the known safety profile of the individual components amlodipine, valsartan and hydrochlorothiazide.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:0in; text-align:justify"><strong><u>Summary of the safety profile</u></strong></p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">The safety of Vittoria HCT has been evaluated at its maximum dose of 10 mg/320 mg/25 mg in one controlled short-term (8 weeks) clinical study with 2,271 patients, 582 of whom received valsartan in combination with amlodipine and hydrochlorothiazide. Adverse reactions were generally mild and transient in nature and only infrequently required discontinuation of therapy. In this active controlled clinical trial, the most common reasons for discontinuation of therapy with Vittoria HCT were dizziness and hypotension (0.7%).</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">In the 8-week controlled clinical study, no significant new or unexpected adverse reactions were observed with triple therapy treatment compared to the known effects of the monotherapy or dual therapy components.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">In the 8-week controlled clinical study, changes in laboratory parameters observed with the combination of Vittoria HCT were minor and consistent with the pharmacological mechanism of action of the monotherapy agents. The presence of valsartan in the triple combination attenuated the hypokalaemic effect of hydrochlorothiazide.</p><p style="text-align:justify"><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions, listed by MedDRA System Organ Class and frequency, concern Vittoria HCT &nbsp;(amlodipine/valsartan/HCT) &nbsp;and &nbsp;amlodipine, &nbsp;valsartan &nbsp;and &nbsp;HCT &nbsp;individually. &nbsp;Very &nbsp;common:</p><p>&ge;1/10; common: &ge;1/100 to &lt;1/10; uncommon: &ge;1/1,000 to &lt;1/100; rare: &ge;1/10,000 to &lt;1/1,000; very</p><p>rare: &lt;1/10,000, not known (cannot be estimated from the available data).</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#8eaadb; height:48.55pt; vertical-align:top; width:93.5pt"><p style="margin-left:12.5pt; margin-right:12.0pt; text-align:center; text-indent:.05pt">MedDRA System Organ Class</p></td><td style="height:48.55pt; vertical-align:top; width:105.2pt"><p>&nbsp;</p><p style="margin-right:8.8pt; text-align:right">Adverse reactions</p></td><td style="height:48.55pt; vertical-align:top; width:78.85pt"><p>&nbsp;</p><p style="margin-right:8.95pt; text-align:right">HCT</p></td><td style="height:48.55pt; vertical-align:top; width:87.55pt"><p>&nbsp;</p><p style="margin-left:14.05pt; margin-right:13.65pt; text-align:center">Amlodipine</p></td><td style="height:48.55pt; vertical-align:top; width:72.25pt"><p>&nbsp;</p><p style="margin-left:8.15pt; margin-right:7.75pt; text-align:center">Valsartan</p></td><td style="height:48.55pt; vertical-align:top; width:68.55pt"><p>&nbsp;</p><p style="margin-left:6.2pt; margin-right:6.0pt; text-align:center">HCT</p></td></tr><tr><td style="background-color:#d9e2f3; border-color:#8eaadb; height:89.9pt; width:93.5pt"><p style="margin-left:6.5pt; margin-right:6.05pt; text-align:center; text-indent:.05pt">Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p></td><td style="background-color:#d9e2f3; height:89.9pt; width:105.2pt"><p style="margin-left:.1in; margin-right:6.7pt; text-align:center; text-indent:-.05pt">Non-melanoma skin cancer (Basal cell carcinoma and Squamous cell carcinoma)</p></td><td style="background-color:#d9e2f3; height:89.9pt; width:78.85pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:34.35pt; margin-right:34.0pt; text-align:center">--</p></td><td style="background-color:#d9e2f3; height:89.9pt; width:87.55pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:14.05pt; margin-right:13.65pt; text-align:center">--</p></td><td style="background-color:#d9e2f3; height:89.9pt; width:72.25pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:8.15pt; margin-right:7.8pt; text-align:center">--</p></td><td style="background-color:#d9e2f3; height:89.9pt; width:68.55pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:6.3pt; margin-right:6.0pt; text-align:center">Not known</p></td></tr><tr><td rowspan="7" style="border-color:#8eaadb; height:48.5pt; vertical-align:top; width:93.5pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:6.5pt; margin-right:5.95pt; text-align:center">Blood and lymphatic system disorders</p></td><td style="height:48.5pt; vertical-align:top; width:105.2pt"><p style="margin-left:9.65pt; margin-right:9.2pt; text-align:center">Agranulocytosis, bone marrow failure</p></td><td style="height:48.5pt; vertical-align:top; width:78.85pt"><p>&nbsp;</p><p style="margin-left:34.35pt; margin-right:34.0pt; text-align:center">--</p></td><td style="height:48.5pt; vertical-align:top; width:87.55pt"><p>&nbsp;</p><p style="margin-left:14.05pt; margin-right:13.65pt; text-align:center">--</p></td><td style="height:48.5pt; vertical-align:top; width:72.25pt"><p>&nbsp;</p><p style="margin-left:8.15pt; margin-right:7.8pt; text-align:center">--</p></td><td style="height:48.5pt; vertical-align:top; width:68.55pt"><p>&nbsp;</p><p style="margin-left:6.3pt; margin-right:6.0pt; text-align:center">Very rare</p></td></tr><tr><td style="background-color:#d9e2f3; height:48.5pt; width:105.2pt"><p style="margin-left:9.65pt; margin-right:9.2pt; text-align:center">Haemoglobin and haematocrit decreased</p></td><td style="background-color:#d9e2f3; height:48.5pt; width:78.85pt"><p>&nbsp;</p><p style="margin-left:34.35pt; margin-right:34.0pt; text-align:center">--</p></td><td style="background-color:#d9e2f3; height:48.5pt; width:87.55pt"><p>&nbsp;</p><p style="margin-left:14.05pt; margin-right:13.65pt; text-align:center">--</p></td><td style="background-color:#d9e2f3; height:48.5pt; width:72.25pt"><p>&nbsp;</p><p style="margin-left:8.15pt; margin-right:7.85pt; text-align:center">Not known</p></td><td style="background-color:#d9e2f3; height:48.5pt; width:68.55pt"><p>&nbsp;</p><p style="margin-left:6.3pt; margin-right:6.0pt; text-align:center">--</p></td></tr><tr><td style="height:34.75pt; vertical-align:top; width:105.2pt"><p style="margin-left:32.5pt; margin-right:23.25pt; text-indent:-8.05pt">Haemolytic anaemia</p></td><td style="height:34.75pt; vertical-align:top; width:78.85pt"><p style="margin-left:34.35pt; margin-right:34.0pt; text-align:center">--</p></td><td style="height:34.75pt; vertical-align:top; width:87.55pt"><p style="margin-left:14.05pt; margin-right:13.65pt; text-align:center">--</p></td><td style="height:34.75pt; vertical-align:top; width:72.25pt"><p style="margin-left:8.15pt; margin-right:7.8pt; text-align:center">--</p></td><td style="height:34.75pt; vertical-align:top; width:68.55pt"><p style="margin-left:6.3pt; margin-right:6.0pt; text-align:center">Very rare</p></td></tr><tr><td style="background-color:#d9e2f3; height:20.9pt; width:105.2pt"><p style="margin-left:24.2pt">Leukopenia</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:78.85pt"><p style="margin-left:34.35pt; margin-right:34.0pt; text-align:center">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:87.55pt"><p style="margin-left:14.05pt; margin-right:13.65pt; text-align:center">Very rare</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:72.25pt"><p>&nbsp;</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:68.55pt"><p style="margin-left:6.3pt; margin-right:6.0pt; text-align:center">Very rare</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:105.2pt"><p style="margin-left:22.85pt; margin-right:0in">Neutropenia</p></td><td style="height:20.95pt; vertical-align:top; width:78.85pt"><p style="margin-left:34.35pt; margin-right:34.0pt; text-align:center">--</p></td><td style="height:20.95pt; vertical-align:top; width:87.55pt"><p style="margin-left:14.05pt; margin-right:13.65pt; text-align:center">--</p></td><td style="height:20.95pt; vertical-align:top; width:72.25pt"><p style="margin-left:8.15pt; margin-right:7.85pt; text-align:center">Not known</p></td><td style="height:20.95pt; vertical-align:top; width:68.55pt"><p style="margin-left:6.3pt; margin-right:6.0pt; text-align:center">--</p></td></tr><tr><td style="background-color:#d9e2f3; height:48.5pt; width:105.2pt"><p style="margin-left:5.35pt; margin-right:4.85pt; text-align:center">Thrombocytopenia, sometimes with purpura</p></td><td style="background-color:#d9e2f3; height:48.5pt; width:78.85pt"><p>&nbsp;</p><p style="margin-left:34.35pt; margin-right:34.0pt; text-align:center">--</p></td><td style="background-color:#d9e2f3; height:48.5pt; width:87.55pt"><p>&nbsp;</p><p style="margin-left:14.05pt; margin-right:13.65pt; text-align:center">Very rare</p></td><td style="background-color:#d9e2f3; height:48.5pt; width:72.25pt"><p>&nbsp;</p><p style="margin-left:8.15pt; margin-right:7.85pt; text-align:center">Not known</p></td><td style="background-color:#d9e2f3; height:48.5pt; width:68.55pt"><p>&nbsp;</p><p style="margin-left:6.25pt; margin-right:6.0pt; text-align:center">Rare</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:105.2pt"><p style="margin-left:0in; margin-right:10.45pt; text-align:right">Aplastic anaemia</p></td><td style="height:20.95pt; vertical-align:top; width:78.85pt"><p style="margin-left:34.35pt; margin-right:34.0pt; text-align:center">--</p></td><td style="height:20.95pt; vertical-align:top; width:87.55pt"><p style="margin-left:14.05pt; margin-right:13.65pt; text-align:center">--</p></td><td style="height:20.95pt; vertical-align:top; width:72.25pt"><p style="margin-left:8.15pt; margin-right:7.8pt; text-align:center">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.55pt"><p style="margin-left:6.3pt; margin-right:6.0pt; text-align:center">Not known</p></td></tr><tr><td style="background-color:#d9e2f3; border-color:#8eaadb; height:34.7pt; width:93.5pt"><p style="margin-left:24.7pt; margin-right:7.15pt; text-indent:-16.2pt">Immune system disorders</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:105.2pt"><p style="margin-left:0in; margin-right:12.35pt; text-align:right">Hypersensitivity</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:78.85pt"><p style="margin-left:34.35pt; margin-right:34.0pt; text-align:center">--</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:87.55pt"><p style="margin-left:14.05pt; margin-right:13.65pt; text-align:center">Very rare</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:72.25pt"><p style="margin-left:8.15pt; margin-right:7.85pt; text-align:center">Not known</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:68.55pt"><p style="margin-left:6.3pt; margin-right:6.0pt; text-align:center">Very rare</p></td></tr><tr><td style="border-color:#8eaadb; height:20.95pt; vertical-align:top; width:93.5pt"><p style="margin-left:7.9pt; margin-right:0in">Metabolism and</p></td><td style="height:20.95pt; vertical-align:top; width:105.2pt"><p style="margin-left:30.2pt; margin-right:0in">Anorexia</p></td><td style="height:20.95pt; vertical-align:top; width:78.85pt"><p style="margin-left:0in; margin-right:10.5pt; text-align:right">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:87.55pt"><p style="margin-left:14.05pt; margin-right:13.65pt; text-align:center">--</p></td><td style="height:20.95pt; vertical-align:top; width:72.25pt"><p style="margin-left:8.15pt; margin-right:7.8pt; text-align:center">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.55pt"><p style="margin-left:6.3pt; margin-right:6.0pt; text-align:center">--</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="9" style="border-color:#8eaadb; height:20.9pt; vertical-align:top; width:93.5pt"><p style="margin-left:24.7pt; margin-right:23.3pt; text-indent:1.3pt">nutrition disorders</p></td><td style="background-color:#d9e2f3; border-color:#8eaadb; height:20.9pt; width:105.2pt"><p style="margin-left:13.55pt">Hypercalcaemia</p></td><td style="background-color:#d9e2f3; border-color:#8eaadb; height:20.9pt; width:78.85pt"><p style="margin-right:10.5pt; text-align:right">Uncommon</p></td><td style="background-color:#d9e2f3; border-color:#8eaadb; height:20.9pt; width:87.55pt"><p style="margin-left:20.85pt">Very rare</p></td><td style="background-color:#d9e2f3; border-color:#8eaadb; height:20.9pt; width:72.25pt"><p>&nbsp;</p></td><td style="background-color:#d9e2f3; border-color:#8eaadb; height:20.9pt; width:68.55pt"><p style="margin-left:22.8pt">Rare</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:105.2pt"><p style="margin-left:12.85pt; margin-right:0in">Hyperglycaemia</p></td><td style="height:20.95pt; vertical-align:top; width:78.85pt"><p style="margin-left:34.35pt; margin-right:34.0pt; text-align:center">--</p></td><td style="height:20.95pt; vertical-align:top; width:87.55pt"><p>&nbsp;</p></td><td style="height:20.95pt; vertical-align:top; width:72.25pt"><p style="margin-left:8.15pt; margin-right:7.8pt; text-align:center">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.55pt"><p style="margin-left:22.8pt; margin-right:0in">Rare</p></td></tr><tr><td style="background-color:#d9e2f3; height:20.9pt; width:105.2pt"><p style="margin-left:5.35pt">Hyperlipidaemia</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:78.85pt"><p style="margin-left:5.35pt">Uncommon</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:87.55pt"><p style="margin-left:5.3pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:72.25pt"><p style="margin-left:5.3pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:68.55pt"><p style="margin-left:5.3pt">--</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:105.2pt"><p style="margin-left:5.35pt; margin-right:0in">Hyperuricaemia</p></td><td style="height:20.95pt; vertical-align:top; width:78.85pt"><p style="margin-left:5.35pt; margin-right:0in">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:87.55pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:72.25pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.55pt"><p style="margin-left:5.3pt; margin-right:0in">Common</p></td></tr><tr><td style="background-color:#d9e2f3; height:34.7pt; width:105.2pt"><p style="margin-left:5.35pt; margin-right:18.35pt">Hypochloraemic alkalosis</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:78.85pt"><p style="margin-left:5.35pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:87.55pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:72.25pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:68.55pt"><p style="margin-left:5.3pt; margin-right:0in">Very rare</p></td></tr><tr><td style="height:34.75pt; vertical-align:top; width:105.2pt"><p style="margin-left:5.35pt; margin-right:0in">Hypokalaemia</p></td><td style="height:34.75pt; vertical-align:top; width:78.85pt"><p style="margin-left:5.3pt; margin-right:0in">common</p></td><td style="height:34.75pt; vertical-align:top; width:87.55pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:72.25pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:68.55pt"><p style="margin-left:5.3pt; margin-right:19.75pt">Very common</p></td></tr><tr><td style="background-color:#d9e2f3; height:20.9pt; width:105.2pt"><p style="margin-left:5.35pt">Hypomagnesaemia</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:78.85pt"><p style="margin-left:5.35pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:87.55pt"><p style="margin-left:5.3pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:72.25pt"><p style="margin-left:5.3pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:68.55pt"><p style="margin-left:5.3pt">common</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:105.2pt"><p style="margin-left:5.35pt">Hyponatraemia</p></td><td style="height:20.95pt; vertical-align:top; width:78.85pt"><p style="margin-left:5.35pt">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:87.55pt"><p style="margin-left:5.3pt">--</p></td><td style="height:20.95pt; vertical-align:top; width:72.25pt"><p style="margin-left:5.3pt">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.55pt"><p style="margin-left:5.3pt">common</p></td></tr><tr><td style="background-color:#d9e2f3; height:48.5pt; width:105.2pt"><p style="margin-left:5.35pt; margin-right:4.75pt; text-align:justify"><strong>Worsening of diabetic metabolic state</strong></p></td><td style="background-color:#d9e2f3; height:48.5pt; width:78.85pt"><p>&nbsp;</p><p style="margin-left:5.35pt">--</p></td><td style="background-color:#d9e2f3; height:48.5pt; width:87.55pt"><p>&nbsp;</p><p style="margin-left:5.3pt">--</p></td><td style="background-color:#d9e2f3; height:48.5pt; width:72.25pt"><p>&nbsp;</p><p style="margin-left:5.3pt">--</p></td><td style="background-color:#d9e2f3; height:48.5pt; width:68.55pt"><p>&nbsp;</p><p style="margin-left:5.3pt">Rare</p></td></tr><tr><td rowspan="4" style="border-color:#8eaadb; height:20.95pt; vertical-align:top; width:93.5pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.85pt; margin-right:24.8pt"><strong>Psychiatric disorders</strong></p></td><td style="height:20.95pt; vertical-align:top; width:105.2pt"><p style="margin-left:5.35pt">Depression</p></td><td style="height:20.95pt; vertical-align:top; width:78.85pt"><p style="margin-left:5.35pt">--</p></td><td style="height:20.95pt; vertical-align:top; width:87.55pt"><p style="margin-left:5.3pt">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:72.25pt"><p style="margin-left:5.3pt">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.55pt"><p style="margin-left:5.3pt">Rare</p></td></tr><tr><td style="background-color:#d9e2f3; height:34.7pt; width:105.2pt"><p style="margin-left:5.35pt; margin-right:25.7pt">Insomnia/sleep disorders</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:78.85pt"><p style="margin-left:5.35pt; margin-right:0in">Uncommon</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:87.55pt"><p style="margin-left:5.3pt; margin-right:0in">Uncommon</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:72.25pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:68.55pt"><p style="margin-left:5.3pt; margin-right:0in">Rare</p></td></tr><tr><td style="height:20.9pt; vertical-align:top; width:105.2pt"><p style="margin-left:5.35pt">Mood swings</p></td><td style="height:20.9pt; vertical-align:top; width:78.85pt"><p style="margin-left:5.35pt">--</p></td><td style="height:20.9pt; vertical-align:top; width:87.55pt"><p style="margin-left:5.3pt">Uncommon</p></td><td style="height:20.9pt; vertical-align:top; width:72.25pt"><p style="margin-left:5.3pt">--</p></td><td style="height:20.9pt; vertical-align:top; width:68.55pt"><p style="margin-left:5.3pt">--</p></td></tr><tr><td style="background-color:#d9e2f3; height:20.95pt; width:105.2pt"><p style="margin-left:5.35pt; margin-right:0in">Confusion</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:78.85pt"><p style="margin-left:5.35pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:87.55pt"><p style="margin-left:5.3pt; margin-right:0in">Rare</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:72.25pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:68.55pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td></tr><tr><td rowspan="10" style="border-color:#8eaadb; height:34.7pt; vertical-align:top; width:93.5pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.85pt; margin-right:34.15pt"><strong>Nervous system disorders</strong></p></td><td style="height:34.7pt; vertical-align:top; width:105.2pt"><p style="margin-left:5.35pt; margin-right:35.0pt">Coordination abnormal</p></td><td style="height:34.7pt; vertical-align:top; width:78.85pt"><p style="margin-left:5.35pt; margin-right:0in">Uncommon</p></td><td style="height:34.7pt; vertical-align:top; width:87.55pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="height:34.7pt; vertical-align:top; width:72.25pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="height:34.7pt; vertical-align:top; width:68.55pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td></tr><tr><td style="background-color:#d9e2f3; height:20.95pt; width:105.2pt"><p style="margin-left:5.35pt; margin-right:0in">Dizziness</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:78.85pt"><p style="margin-left:5.35pt; margin-right:0in">Common</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:87.55pt"><p style="margin-left:5.3pt; margin-right:0in">Common</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:72.25pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:68.55pt"><p style="margin-left:5.3pt; margin-right:0in">Rare</p></td></tr><tr><td style="height:48.5pt; vertical-align:top; width:105.2pt"><p style="margin-left:5.35pt; margin-right:7.35pt">Dizziness postural, dizziness exertional</p></td><td style="height:48.5pt; vertical-align:top; width:78.85pt"><p>&nbsp;</p><p style="margin-left:5.35pt">Uncommon</p></td><td style="height:48.5pt; vertical-align:top; width:87.55pt"><p>&nbsp;</p><p style="margin-left:5.3pt">--</p></td><td style="height:48.5pt; vertical-align:top; width:72.25pt"><p>&nbsp;</p><p style="margin-left:5.3pt">--</p></td><td style="height:48.5pt; vertical-align:top; width:68.55pt"><p>&nbsp;</p><p style="margin-left:5.3pt">--</p></td></tr><tr><td style="background-color:#d9e2f3; height:20.95pt; width:105.2pt"><p style="margin-left:5.35pt; margin-right:0in">Dysgeusia</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:78.85pt"><p style="margin-left:5.35pt; margin-right:0in">Uncommon</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:87.55pt"><p style="margin-left:5.3pt; margin-right:0in">Uncommon</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:72.25pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:68.55pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td></tr><tr><td style="height:34.7pt; vertical-align:top; width:105.2pt"><p style="margin-left:5.35pt; margin-right:23.7pt">Extrapyramidal syndrome</p></td><td style="height:34.7pt; vertical-align:top; width:78.85pt"><p style="margin-left:5.35pt; margin-right:0in">--</p></td><td style="height:34.7pt; vertical-align:top; width:87.55pt"><p style="margin-left:5.3pt; margin-right:0in">Not known</p></td><td style="height:34.7pt; vertical-align:top; width:72.25pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="height:34.7pt; vertical-align:top; width:68.55pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td></tr><tr><td style="background-color:#d9e2f3; height:20.95pt; width:105.2pt"><p style="margin-left:5.35pt; margin-right:0in">Headache</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:78.85pt"><p style="margin-left:5.35pt; margin-right:0in">Common</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:87.55pt"><p style="margin-left:5.3pt; margin-right:0in">Common</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:72.25pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:68.55pt"><p style="margin-left:5.3pt; margin-right:0in">Rare</p></td></tr><tr><td style="height:20.9pt; vertical-align:top; width:105.2pt"><p style="margin-left:5.35pt">Hypertonia</p></td><td style="height:20.9pt; vertical-align:top; width:78.85pt"><p style="margin-left:5.35pt">--</p></td><td style="height:20.9pt; vertical-align:top; width:87.55pt"><p style="margin-left:5.3pt">Very rare</p></td><td style="height:20.9pt; vertical-align:top; width:72.25pt"><p style="margin-left:5.3pt">--</p></td><td style="height:20.9pt; vertical-align:top; width:68.55pt"><p style="margin-left:5.3pt">--</p></td></tr><tr><td style="background-color:#d9e2f3; height:20.95pt; width:105.2pt"><p style="margin-left:5.35pt; margin-right:0in">Lethargy</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:78.85pt"><p style="margin-left:5.35pt; margin-right:0in">Uncommon</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:87.55pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:72.25pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:68.55pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td></tr><tr><td style="height:20.9pt; vertical-align:top; width:105.2pt"><p style="margin-left:5.35pt">Paraesthesia</p></td><td style="height:20.9pt; vertical-align:top; width:78.85pt"><p style="margin-left:5.35pt">Uncommon</p></td><td style="height:20.9pt; vertical-align:top; width:87.55pt"><p style="margin-left:5.3pt">Uncommon</p></td><td style="height:20.9pt; vertical-align:top; width:72.25pt"><p style="margin-left:5.3pt">--</p></td><td style="height:20.9pt; vertical-align:top; width:68.55pt"><p style="margin-left:5.3pt">Rare</p></td></tr><tr><td style="background-color:#d9e2f3; height:27.6pt; width:105.2pt"><p style="margin-left:9.55pt; margin-right:37.15pt">Peripheral neuropathy,</p></td><td style="background-color:#d9e2f3; height:27.6pt; width:78.85pt"><p style="margin-left:0in; margin-right:12.0pt; text-align:right">Uncommon</p></td><td style="background-color:#d9e2f3; height:27.6pt; width:87.55pt"><p style="margin-left:9.5pt; margin-right:0in">Very rare</p></td><td style="background-color:#d9e2f3; height:27.6pt; width:72.25pt"><p style="margin-left:9.5pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:27.6pt; width:68.55pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="5" style="border-color:#8eaadb; height:20.9pt; vertical-align:top; width:93.5pt"><p>&nbsp;</p></td><td style="background-color:#d9e2f3; border-color:#8eaadb; height:20.9pt; width:105.2pt"><p style="margin-left:9.55pt">neuropathy</p></td><td style="background-color:#d9e2f3; border-color:#8eaadb; height:20.9pt; width:78.85pt"><p>&nbsp;</p></td><td style="background-color:#d9e2f3; border-color:#8eaadb; height:20.9pt; width:87.55pt"><p>&nbsp;</p></td><td style="background-color:#d9e2f3; border-color:#8eaadb; height:20.9pt; width:72.25pt"><p>&nbsp;</p></td><td style="background-color:#d9e2f3; border-color:#8eaadb; height:20.9pt; width:68.55pt"><p>&nbsp;</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:105.2pt"><p style="margin-left:9.55pt; margin-right:0in">Somnolence</p></td><td style="height:20.95pt; vertical-align:top; width:78.85pt"><p style="margin-left:9.55pt; margin-right:0in">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:87.55pt"><p style="margin-left:9.5pt; margin-right:0in">Common</p></td><td style="height:20.95pt; vertical-align:top; width:72.25pt"><p style="margin-left:9.5pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.55pt"><p>&nbsp;</p></td></tr><tr><td style="background-color:#d9e2f3; height:20.9pt; width:105.2pt"><p style="margin-left:9.55pt">Syncope</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:78.85pt"><p style="margin-left:9.55pt">Uncommon</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:87.55pt"><p style="margin-left:9.5pt">Uncommon</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:72.25pt"><p style="margin-left:9.5pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:68.55pt"><p>&nbsp;</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:105.2pt"><p style="margin-left:9.55pt; margin-right:0in">Tremor</p></td><td style="height:20.95pt; vertical-align:top; width:78.85pt"><p style="margin-left:9.55pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:87.55pt"><p style="margin-left:9.5pt; margin-right:0in">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:72.25pt"><p style="margin-left:9.5pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.55pt"><p>&nbsp;</p></td></tr><tr><td style="background-color:#d9e2f3; height:20.9pt; width:105.2pt"><p style="margin-left:9.55pt">Hypoesthesia</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:78.85pt"><p style="margin-left:9.55pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:87.55pt"><p style="margin-left:9.5pt">Uncommon</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:72.25pt"><p style="margin-left:9.5pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:68.55pt"><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="border-color:#8eaadb; height:34.75pt; vertical-align:top; width:93.5pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.35pt"><strong>Eye disorders</strong></p></td><td style="height:34.75pt; vertical-align:top; width:105.2pt"><p style="margin-left:9.55pt; margin-right:4.8pt">Acute&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angle- closure glaucoma</p></td><td style="height:34.75pt; vertical-align:top; width:78.85pt"><p style="margin-left:9.55pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:87.55pt"><p style="margin-left:9.5pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:72.25pt"><p style="margin-left:9.5pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:68.55pt"><p style="margin-left:.45pt; margin-right:0in">ot known</p></td></tr><tr><td style="background-color:#d9e2f3; height:20.9pt; width:105.2pt"><p style="margin-left:9.55pt">Visual disturbance</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:78.85pt"><p style="margin-left:9.55pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:87.55pt"><p style="margin-left:9.5pt">Uncommon</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:72.25pt"><p style="margin-left:9.5pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:68.55pt"><p>&nbsp;</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:105.2pt"><p style="margin-left:9.55pt">Visual impairment</p></td><td style="height:20.95pt; vertical-align:top; width:78.85pt"><p style="margin-left:9.55pt">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:87.55pt"><p style="margin-left:9.5pt">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:72.25pt"><p style="margin-left:9.5pt">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.55pt"><p style="margin-left:-.2pt">are</p></td></tr><tr><td rowspan="2" style="background-color:#d9e2f3; border-color:#8eaadb; height:20.9pt; width:93.5pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.35pt; margin-right:0in"><strong>Ear&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</strong></p><p style="margin-left:5.35pt; margin-right:38.6pt"><strong>labyrinth disorders</strong></p></td><td style="background-color:#d9e2f3; height:20.9pt; width:105.2pt"><p style="margin-left:9.55pt">Tinnitus</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:78.85pt"><p style="margin-left:9.55pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:87.55pt"><p style="margin-left:9.5pt">Uncommon</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:72.25pt"><p style="margin-left:9.5pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:68.55pt"><p>&nbsp;</p></td></tr><tr><td style="height:104.7pt; vertical-align:top; width:105.2pt"><p>&nbsp;</p><p style="margin-left:9.55pt">Vertigo</p></td><td style="height:104.7pt; vertical-align:top; width:78.85pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.55pt">Uncommon</p></td><td style="height:104.7pt; vertical-align:top; width:87.55pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.5pt">--</p></td><td style="height:104.7pt; vertical-align:top; width:72.25pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.5pt">Uncommon</p></td><td style="height:104.7pt; vertical-align:top; width:68.55pt"><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="background-color:#d9e2f3; border-color:#8eaadb; height:20.95pt; width:93.5pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.35pt; margin-right:38.65pt"><strong>Cardiac disorders</strong></p></td><td style="background-color:#d9e2f3; height:20.95pt; width:105.2pt"><p style="margin-left:9.55pt">Palpitations</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:78.85pt"><p style="margin-left:9.55pt">--</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:87.55pt"><p>&nbsp;</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:72.25pt"><p style="margin-left:9.5pt">--</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:68.55pt"><p>&nbsp;</p></td></tr><tr><td style="height:20.9pt; vertical-align:top; width:105.2pt"><p style="margin-left:9.55pt">Tachycardia</p></td><td style="height:20.9pt; vertical-align:top; width:78.85pt"><p style="margin-left:9.55pt">Uncommon</p></td><td style="height:20.9pt; vertical-align:top; width:87.55pt"><p style="margin-left:9.5pt">--</p></td><td style="height:20.9pt; vertical-align:top; width:72.25pt"><p style="margin-left:9.5pt">--</p></td><td style="height:20.9pt; vertical-align:top; width:68.55pt"><p>&nbsp;</p></td></tr><tr><td style="background-color:#d9e2f3; height:89.95pt; width:105.2pt"><p style="margin-left:9.55pt; margin-right:4.85pt">Arrhythmias (including bradycardia, ventricular tachycardia,&nbsp;&nbsp;&nbsp;&nbsp; and atrial fibrillation)</p></td><td style="background-color:#d9e2f3; height:89.95pt; width:78.85pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.55pt">--</p></td><td style="background-color:#d9e2f3; height:89.95pt; width:87.55pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.5pt">Very rare</p></td><td style="background-color:#d9e2f3; height:89.95pt; width:72.25pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.5pt">--</p></td><td style="background-color:#d9e2f3; height:89.95pt; width:68.55pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:-.2pt">are</p></td></tr><tr><td style="height:34.7pt; vertical-align:top; width:105.2pt"><p style="margin-left:9.55pt; margin-right:38.8pt">Myocardial infarction</p></td><td style="height:34.7pt; vertical-align:top; width:78.85pt"><p style="margin-left:9.55pt; margin-right:0in">--</p></td><td style="height:34.7pt; vertical-align:top; width:87.55pt"><p style="margin-left:9.5pt; margin-right:0in">Veery rare</p></td><td style="height:34.7pt; vertical-align:top; width:72.25pt"><p style="margin-left:9.5pt; margin-right:0in">--</p></td><td style="height:34.7pt; vertical-align:top; width:68.55pt"><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="background-color:#d9e2f3; border-color:#8eaadb; height:20.9pt; width:93.5pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.35pt; margin-right:38.65pt"><strong>Vascular disorders</strong></p></td><td style="background-color:#d9e2f3; height:20.9pt; width:105.2pt"><p style="margin-left:9.55pt">Flushing</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:78.85pt"><p style="margin-left:9.55pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:87.55pt"><p style="margin-left:9.5pt">Common</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:72.25pt"><p style="margin-left:9.5pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:68.55pt"><p>&nbsp;</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:105.2pt"><p style="margin-left:9.55pt; margin-right:0in">Hypotension</p></td><td style="height:20.95pt; vertical-align:top; width:78.85pt"><p style="margin-left:9.55pt; margin-right:0in">Common</p></td><td style="height:20.95pt; vertical-align:top; width:87.55pt"><p style="margin-left:9.5pt; margin-right:0in">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:72.25pt"><p style="margin-left:9.5pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.55pt"><p>&nbsp;</p></td></tr><tr><td style="background-color:#d9e2f3; height:34.7pt; width:105.2pt"><p style="margin-left:9.55pt; margin-right:35.45pt">Orthostatic hypotension</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:78.85pt"><p style="margin-left:9.55pt; margin-right:0in">Uncommon</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:87.55pt"><p style="margin-left:9.5pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:72.25pt"><p style="margin-left:9.5pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:34.7pt; width:68.55pt"><p>&nbsp;</p></td></tr><tr><td style="height:34.75pt; vertical-align:top; width:105.2pt"><p style="margin-left:9.55pt; margin-right:12.15pt">Phlebitis, thrombophlebitis</p></td><td style="height:34.75pt; vertical-align:top; width:78.85pt"><p style="margin-left:9.55pt; margin-right:0in">Uncommon</p></td><td style="height:34.75pt; vertical-align:top; width:87.55pt"><p style="margin-left:9.5pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:72.25pt"><p style="margin-left:9.5pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:68.55pt"><p>&nbsp;</p></td></tr><tr><td style="background-color:#d9e2f3; height:20.95pt; width:105.2pt"><p style="margin-left:9.55pt">Vasculitis</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:78.85pt"><p style="margin-left:9.55pt">--</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:87.55pt"><p style="margin-left:9.5pt">Very rare</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:72.25pt"><p style="margin-left:9.5pt">Not known</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:68.55pt"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="5" style="border-color:#8eaadb; height:20.9pt; vertical-align:top; width:93.5pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.35pt; margin-right:4.8pt"><strong>Respiratory, thoracic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and mediastinal disorders</strong></p></td><td style="border-color:#8eaadb; height:20.9pt; vertical-align:top; width:105.2pt"><p style="margin-left:5.35pt">Cough</p></td><td style="border-color:#8eaadb; height:20.9pt; vertical-align:top; width:78.85pt"><p style="margin-left:5.35pt">Uncommon</p></td><td style="border-color:#8eaadb; height:20.9pt; vertical-align:top; width:87.55pt"><p style="margin-left:5.3pt">Very rare</p></td><td style="border-color:#8eaadb; height:20.9pt; vertical-align:top; width:72.25pt"><p style="margin-left:5.3pt">Uncommon</p></td><td style="border-color:#8eaadb; height:20.9pt; vertical-align:top; width:68.55pt"><p style="margin-left:5.3pt">--</p></td></tr><tr><td style="background-color:#d9e2f3; height:20.95pt; width:105.2pt"><p style="margin-left:5.35pt; margin-right:0in">Dyspnoea</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:78.85pt"><p style="margin-left:5.35pt; margin-right:0in">Uncommon</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:87.55pt"><p style="margin-left:5.3pt; margin-right:0in">Uncommon</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:72.25pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:68.55pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td></tr><tr><td style="height:62.3pt; vertical-align:top; width:105.2pt"><p style="margin-left:5.35pt; margin-right:4.35pt">Respiratory distress, pulmonary oedema, pneumonitis</p></td><td style="height:62.3pt; vertical-align:top; width:78.85pt"><p>&nbsp;</p><p style="margin-left:5.35pt">--</p></td><td style="height:62.3pt; vertical-align:top; width:87.55pt"><p>&nbsp;</p><p style="margin-left:5.3pt">--</p></td><td style="height:62.3pt; vertical-align:top; width:72.25pt"><p>&nbsp;</p><p style="margin-left:5.3pt">--</p></td><td style="height:62.3pt; vertical-align:top; width:68.55pt"><p>&nbsp;</p><p style="margin-left:5.3pt">Very rare</p></td></tr><tr><td style="background-color:#d9e2f3; height:20.95pt; width:105.2pt"><p style="margin-left:5.35pt; margin-right:0in">Rhinitis</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:78.85pt"><p style="margin-left:5.35pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:87.55pt"><p style="margin-left:5.3pt; margin-right:0in">Uncommon</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:72.25pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:68.55pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td></tr><tr><td style="height:20.9pt; vertical-align:top; width:105.2pt"><p style="margin-left:5.35pt">Throat irritation</p></td><td style="height:20.9pt; vertical-align:top; width:78.85pt"><p style="margin-left:5.35pt">Uncommon</p></td><td style="height:20.9pt; vertical-align:top; width:87.55pt"><p style="margin-left:5.3pt">--</p></td><td style="height:20.9pt; vertical-align:top; width:72.25pt"><p style="margin-left:5.3pt">--</p></td><td style="height:20.9pt; vertical-align:top; width:68.55pt"><p style="margin-left:5.3pt">--</p></td></tr><tr><td rowspan="7" style="background-color:#d9e2f3; border-color:#8eaadb; height:62.35pt; width:93.5pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.35pt; margin-right:3.95pt"><strong>Gastrointestinal disorders</strong></p></td><td style="background-color:#d9e2f3; height:62.35pt; width:105.2pt"><p style="margin-left:5.35pt; margin-right:4.85pt">Abdominal discomfort, abdominal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain upper</p></td><td style="background-color:#d9e2f3; height:62.35pt; width:78.85pt"><p>&nbsp;</p><p style="margin-left:5.35pt">Uncommon</p></td><td style="background-color:#d9e2f3; height:62.35pt; width:87.55pt"><p>&nbsp;</p><p style="margin-left:5.3pt">Common</p></td><td style="background-color:#d9e2f3; height:62.35pt; width:72.25pt"><p>&nbsp;</p></td><td style="background-color:#d9e2f3; height:62.35pt; width:68.55pt"><p>&nbsp;</p></td></tr><tr><td style="height:20.9pt; vertical-align:top; width:105.2pt"><p style="margin-left:5.35pt">Breath odour</p></td><td style="height:20.9pt; vertical-align:top; width:78.85pt"><p style="margin-left:5.35pt">Uncommon</p></td><td style="height:20.9pt; vertical-align:top; width:87.55pt"><p style="margin-left:5.3pt">--</p></td><td style="height:20.9pt; vertical-align:top; width:72.25pt"><p style="margin-left:5.3pt">--</p></td><td style="height:20.9pt; vertical-align:top; width:68.55pt"><p style="margin-left:5.3pt">--</p></td></tr><tr><td style="background-color:#d9e2f3; height:34.75pt; width:105.2pt"><p style="margin-left:5.35pt">Change of bowel habit</p></td><td style="background-color:#d9e2f3; height:34.75pt; width:78.85pt"><p style="margin-left:5.35pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:34.75pt; width:87.55pt"><p style="margin-left:5.3pt; margin-right:0in">Uncommon</p></td><td style="background-color:#d9e2f3; height:34.75pt; width:72.25pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="background-color:#d9e2f3; height:34.75pt; width:68.55pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td></tr><tr><td style="height:20.9pt; vertical-align:top; width:105.2pt"><p style="margin-left:5.35pt">Constipation</p></td><td style="height:20.9pt; vertical-align:top; width:78.85pt"><p style="margin-left:5.35pt">--</p></td><td style="height:20.9pt; vertical-align:top; width:87.55pt"><p style="margin-left:5.3pt">--</p></td><td style="height:20.9pt; vertical-align:top; width:72.25pt"><p style="margin-left:5.3pt">--</p></td><td style="height:20.9pt; vertical-align:top; width:68.55pt"><p style="margin-left:5.3pt">Rare</p></td></tr><tr><td style="background-color:#d9e2f3; height:20.9pt; width:105.2pt"><p style="margin-left:5.35pt">Decreased appetite</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:78.85pt"><p style="margin-left:5.35pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:87.55pt"><p style="margin-left:5.3pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:72.25pt"><p style="margin-left:5.3pt">--</p></td><td style="background-color:#d9e2f3; height:20.9pt; width:68.55pt"><p style="margin-left:5.3pt">Common</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:105.2pt"><p style="margin-left:5.35pt; margin-right:0in">Diarrhoea</p></td><td style="height:20.95pt; vertical-align:top; width:78.85pt"><p style="margin-left:5.35pt; margin-right:0in">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:87.55pt"><p style="margin-left:5.3pt; margin-right:0in">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:72.25pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.55pt"><p style="margin-left:5.3pt; margin-right:0in">Rare</p></td></tr><tr><td style="background-color:#d9e2f3; height:20.95pt; width:105.2pt"><p style="margin-left:5.35pt">Dry mouth</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:78.85pt"><p style="margin-left:5.35pt">Uncommon</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:87.55pt"><p style="margin-left:5.3pt">Uncommon</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:72.25pt"><p style="margin-left:5.3pt">--</p></td><td style="background-color:#d9e2f3; height:20.95pt; width:68.55pt"><p style="margin-left:5.3pt">--</p></td></tr></tbody></table><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="6" style="border-color:#4472c4; height:20.95pt; vertical-align:top; width:93.5pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.35pt; margin-right:3.45pt"><strong>Gastrointestinal disorders</strong></p></td><td style="height:20.95pt; vertical-align:top; width:84.75pt"><p style="margin-left:5.35pt; margin-right:0in">Dyspepsia</p></td><td style="height:20.95pt; vertical-align:top; width:83.5pt"><p style="margin-left:5.3pt; margin-right:0in">Common</p></td><td style="height:20.95pt; vertical-align:top; width:83.5pt"><p style="margin-left:5.25pt; margin-right:0in">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:79.9pt"><p style="margin-left:5.25pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:80.85pt"><p style="margin-left:5.15pt; margin-right:0in">--</p></td></tr><tr><td style="background-color:#d0dbf0; height:20.9pt; width:84.75pt"><p style="margin-left:5.35pt">Gastritis</p></td><td style="background-color:#d0dbf0; height:20.9pt; width:83.5pt"><p style="margin-left:5.3pt">--</p></td><td style="background-color:#d0dbf0; height:20.9pt; width:83.5pt"><p style="margin-left:5.25pt">Very rare</p></td><td style="background-color:#d0dbf0; height:20.9pt; width:79.9pt"><p style="margin-left:5.25pt">--</p></td><td style="background-color:#d0dbf0; height:20.9pt; width:80.85pt"><p style="margin-left:5.15pt">--</p></td></tr><tr><td style="height:34.75pt; vertical-align:top; width:84.75pt"><p style="margin-left:5.35pt; margin-right:22.05pt">Gingival hyperplasia</p></td><td style="height:34.75pt; vertical-align:top; width:83.5pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:83.5pt"><p style="margin-left:5.25pt; margin-right:0in">Very rare</p></td><td style="height:34.75pt; vertical-align:top; width:79.9pt"><p style="margin-left:5.25pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:80.85pt"><p style="margin-left:5.15pt; margin-right:0in">--</p></td></tr><tr><td style="background-color:#d0dbf0; height:20.95pt; width:84.75pt"><p style="margin-left:5.35pt; margin-right:0in">Nausea</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:83.5pt"><p style="margin-left:5.3pt; margin-right:0in">Uncommon</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:83.5pt"><p style="margin-left:5.25pt; margin-right:0in">Common</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:79.9pt"><p style="margin-left:5.25pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:80.85pt"><p style="margin-left:5.15pt; margin-right:0in">Common</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:84.75pt"><p style="margin-left:5.35pt; margin-right:0in">Pancreatitis</p></td><td style="height:20.95pt; vertical-align:top; width:83.5pt"><p>&nbsp;</p></td><td style="height:20.95pt; vertical-align:top; width:83.5pt"><p style="margin-left:5.25pt; margin-right:0in">Very rare</p></td><td style="height:20.95pt; vertical-align:top; width:79.9pt"><p style="margin-left:5.25pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:80.85pt"><p style="margin-left:5.15pt; margin-right:0in">Very rare</p></td></tr><tr><td style="background-color:#d0dbf0; height:20.95pt; width:84.75pt"><p style="margin-left:5.35pt">Vomiting</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:83.5pt"><p style="margin-left:5.3pt">Uncommon</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:83.5pt"><p style="margin-left:5.25pt">Uncommon</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:79.9pt"><p style="margin-left:5.25pt">--</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:80.85pt"><p style="margin-left:5.15pt">Common</p></td></tr><tr><td rowspan="2" style="border-color:#4472c4; height:76.1pt; vertical-align:top; width:93.5pt"><p style="margin-left:5.35pt; margin-right:14.8pt"><strong>Hepatobiliary disorders</strong></p></td><td style="height:76.1pt; vertical-align:top; width:84.75pt"><p style="margin-left:5.35pt; margin-right:5.7pt">Liver function test abnormal, including blood bilirubin increase</p></td><td style="height:76.1pt; vertical-align:top; width:83.5pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.3pt">--</p></td><td style="height:76.1pt; vertical-align:top; width:83.5pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.25pt">Very rare</p></td><td style="height:76.1pt; vertical-align:top; width:79.9pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.25pt">Not known</p></td><td style="height:76.1pt; vertical-align:top; width:80.85pt"><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.15pt">--</p></td></tr><tr><td style="background-color:#d0dbf0; height:21.0pt; width:84.75pt"><p style="margin-left:5.35pt; margin-right:0in">Hepatitis</p></td><td style="background-color:#d0dbf0; height:21.0pt; width:83.5pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:21.0pt; width:83.5pt"><p style="margin-left:5.25pt; margin-right:0in">Very rare</p></td><td style="background-color:#d0dbf0; height:21.0pt; width:79.9pt"><p style="margin-left:5.25pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:21.0pt; width:80.85pt"><p style="margin-left:5.15pt; margin-right:0in">--</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#4472c4; height:48.55pt; vertical-align:top; width:93.5pt"><p>&nbsp;</p></td><td style="border-color:#4472c4; height:48.55pt; vertical-align:top; width:84.75pt"><p style="margin-left:5.35pt; margin-right:20.9pt; text-align:justify">Intrahepatic cholestasis, jaundice</p></td><td style="border-color:#4472c4; height:48.55pt; vertical-align:top; width:83.5pt"><p>&nbsp;</p><p style="margin-left:5.3pt">--</p></td><td style="border-color:#4472c4; height:48.55pt; vertical-align:top; width:83.5pt"><p>&nbsp;</p><p style="margin-left:5.25pt">Very rare</p></td><td style="border-color:#4472c4; height:48.55pt; vertical-align:top; width:79.9pt"><p>&nbsp;</p><p style="margin-left:5.25pt">--</p></td><td style="border-color:#4472c4; height:48.55pt; vertical-align:top; width:80.85pt"><p>&nbsp;</p><p style="margin-left:5.15pt">Rare</p></td></tr><tr><td rowspan="7" style="background-color:#d0dbf0; border-color:#4472c4; height:20.85pt; width:93.5pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.35pt; margin-right:0in">Skin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p style="margin-left:5.35pt; margin-right:11.8pt">subcutaneous tissue disorders</p></td><td style="background-color:#d0dbf0; height:20.85pt; width:84.75pt"><p style="margin-left:5.35pt">Alopecia</p></td><td style="background-color:#d0dbf0; height:20.85pt; width:83.5pt"><p style="margin-left:5.3pt">--</p></td><td style="background-color:#d0dbf0; height:20.85pt; width:83.5pt"><p>&nbsp;</p></td><td style="background-color:#d0dbf0; height:20.85pt; width:79.9pt"><p>&nbsp;</p></td><td style="background-color:#d0dbf0; height:20.85pt; width:80.85pt"><p>&nbsp;</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:84.75pt"><p style="margin-left:5.35pt; margin-right:0in">Angioedema</p></td><td style="height:20.95pt; vertical-align:top; width:83.5pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:83.5pt"><p>&nbsp;</p></td><td style="height:20.95pt; vertical-align:top; width:79.9pt"><p>&nbsp;</p></td><td style="height:20.95pt; vertical-align:top; width:80.85pt"><p>&nbsp;</p></td></tr><tr><td style="background-color:#d0dbf0; height:34.75pt; width:84.75pt"><p style="margin-left:5.35pt; margin-right:26.7pt">Dermatitis bullous</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:83.5pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:83.5pt"><p>&nbsp;</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:79.9pt"><p>&nbsp;</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:80.85pt"><p>&nbsp;</p></td></tr><tr><td style="height:117.55pt; vertical-align:top; width:84.75pt"><p style="margin-left:5.35pt; margin-right:4.35pt">Cutaneous lupus erythematosus- like reactions, reactivation of cutaneous lupus erythematosus</p></td><td style="height:117.55pt; vertical-align:top; width:83.5pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.3pt">--</p></td><td style="height:117.55pt; vertical-align:top; width:83.5pt"><p>&nbsp;</p></td><td style="height:117.55pt; vertical-align:top; width:79.9pt"><p>&nbsp;</p></td><td style="height:117.55pt; vertical-align:top; width:80.85pt"><p>&nbsp;</p></td></tr><tr><td style="background-color:#d0dbf0; height:34.65pt; width:84.75pt"><p style="margin-left:5.35pt; margin-right:23.4pt">Erythema multiforme</p></td><td style="background-color:#d0dbf0; height:34.65pt; width:83.5pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:34.65pt; width:83.5pt"><p>&nbsp;</p></td><td style="background-color:#d0dbf0; height:34.65pt; width:79.9pt"><p>&nbsp;</p></td><td style="background-color:#d0dbf0; height:34.65pt; width:80.85pt"><p>&nbsp;</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:84.75pt"><p style="margin-left:5.35pt; margin-right:0in">Exanthema</p></td><td style="height:20.95pt; vertical-align:top; width:83.5pt"><p style="margin-left:5.3pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:83.5pt"><p>&nbsp;</p></td><td style="height:20.95pt; vertical-align:top; width:79.9pt"><p>&nbsp;</p></td><td style="height:20.95pt; vertical-align:top; width:80.85pt"><p>&nbsp;</p></td></tr><tr><td style="background-color:#d0dbf0; height:21.0pt; width:84.75pt"><p style="margin-left:5.35pt; margin-right:0in">Hyperhidrosis</p></td><td style="background-color:#d0dbf0; height:21.0pt; width:83.5pt"><p style="margin-left:5.3pt; margin-right:0in">Unknown</p></td><td style="background-color:#d0dbf0; height:21.0pt; width:83.5pt"><p>&nbsp;</p></td><td style="background-color:#d0dbf0; height:21.0pt; width:79.9pt"><p>&nbsp;</p></td><td style="background-color:#d0dbf0; height:21.0pt; width:80.85pt"><p>&nbsp;</p></td></tr></tbody></table><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="8" style="border-color:#4472c4; height:34.75pt; vertical-align:top; width:94.0pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.85pt">Skin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p style="margin-left:9.85pt; margin-right:7.8pt">subcutaneous tissue disorders</p></td><td style="height:34.75pt; vertical-align:top; width:96.7pt"><p style="margin-left:9.9pt; margin-right:7.45pt">Photosensitivity reaction*</p></td><td style="height:34.75pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">Very rare</p></td><td style="height:34.75pt; vertical-align:top; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">Rare</p></td></tr><tr><td style="background-color:#d0dbf0; height:20.9pt; width:96.7pt"><p style="margin-left:9.9pt">Pruritus</p></td><td style="background-color:#d0dbf0; height:20.9pt; width:87.05pt"><p style="margin-left:9.9pt">Uncommon</p></td><td style="background-color:#d0dbf0; height:20.9pt; width:87.05pt"><p style="margin-left:9.9pt">Uncommon</p></td><td style="background-color:#d0dbf0; height:20.9pt; width:1.0in"><p style="margin-left:9.9pt">Not known</p></td><td style="background-color:#d0dbf0; height:20.9pt; width:68.95pt"><p style="margin-left:9.9pt">--</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:96.7pt"><p style="margin-left:9.9pt; margin-right:0in">Purpura</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">Rare</p></td></tr><tr><td style="background-color:#d0dbf0; height:20.95pt; width:96.7pt"><p style="margin-left:9.9pt; margin-right:0in">Rash</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">Uncommon</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">Not known</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">Common</p></td></tr><tr><td style="height:34.75pt; vertical-align:top; width:96.7pt"><p style="margin-left:9.9pt; margin-right:22.1pt">Skin discoloration</p></td><td style="height:34.75pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">Uncommon</p></td><td style="height:34.75pt; vertical-align:top; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="background-color:#d0dbf0; height:48.55pt; width:96.7pt"><p style="margin-left:9.9pt; margin-right:4.2pt; text-align:justify">Urticaria and other forms of rash</p></td><td style="background-color:#d0dbf0; height:48.55pt; width:87.05pt"><p>&nbsp;</p><p style="margin-left:9.9pt">--</p></td><td style="background-color:#d0dbf0; height:48.55pt; width:87.05pt"><p>&nbsp;</p><p style="margin-left:9.9pt">Very rare</p></td><td style="background-color:#d0dbf0; height:48.55pt; width:1.0in"><p>&nbsp;</p><p style="margin-left:9.9pt">--</p></td><td style="background-color:#d0dbf0; height:48.55pt; width:68.95pt"><p>&nbsp;</p><p style="margin-left:9.9pt">Common</p></td></tr><tr><td style="height:62.3pt; vertical-align:top; width:96.7pt"><p style="margin-left:9.9pt; margin-right:4.2pt">Vasculitis necrotising&nbsp;&nbsp;&nbsp; and toxic epidermal necrolysis</p></td><td style="height:62.3pt; vertical-align:top; width:87.05pt"><p>&nbsp;</p><p style="margin-left:9.9pt">--</p></td><td style="height:62.3pt; vertical-align:top; width:87.05pt"><p>&nbsp;</p><p style="margin-left:9.9pt">Not known</p></td><td style="height:62.3pt; vertical-align:top; width:1.0in"><p>&nbsp;</p><p style="margin-left:9.9pt">--</p></td><td style="height:62.3pt; vertical-align:top; width:68.95pt"><p>&nbsp;</p><p style="margin-left:9.9pt; margin-right:15.05pt">Very common</p></td></tr><tr><td style="background-color:#d0dbf0; height:21.0pt; width:96.7pt"><p style="margin-left:12.25pt; margin-right:0in">Exfoliative</p></td><td style="background-color:#d0dbf0; height:21.0pt; width:87.05pt"><p style="margin-left:12.3pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:21.0pt; width:87.05pt"><p style="margin-left:12.3pt; margin-right:0in">Very rare</p></td><td style="background-color:#d0dbf0; height:21.0pt; width:1.0in"><p style="margin-left:12.3pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:21.0pt; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="3" style="border-color:#4472c4; height:20.95pt; vertical-align:top; width:94.0pt"><p>&nbsp;</p></td><td style="background-color:#d0dbf0; border-color:#4472c4; height:20.95pt; width:96.7pt"><p style="margin-left:12.25pt">dermatitis</p></td><td style="background-color:#d0dbf0; border-color:#4472c4; height:20.95pt; width:87.05pt"><p>&nbsp;</p></td><td style="background-color:#d0dbf0; border-color:#4472c4; height:20.95pt; width:87.05pt"><p>&nbsp;</p></td><td style="background-color:#d0dbf0; border-color:#4472c4; height:20.95pt; width:1.0in"><p>&nbsp;</p></td><td style="background-color:#d0dbf0; border-color:#4472c4; height:20.95pt; width:68.95pt"><p>&nbsp;</p></td></tr><tr><td style="height:48.5pt; vertical-align:top; width:96.7pt"><p style="margin-left:12.25pt; margin-right:35.1pt">Stevens- Johnson syndrome</p></td><td style="height:48.5pt; vertical-align:top; width:87.05pt"><p>&nbsp;</p><p style="margin-left:12.3pt">--</p></td><td style="height:48.5pt; vertical-align:top; width:87.05pt"><p>&nbsp;</p><p style="margin-left:12.3pt">Very rare</p></td><td style="height:48.5pt; vertical-align:top; width:1.0in"><p>&nbsp;</p><p style="margin-left:12.3pt">--</p></td><td style="height:48.5pt; vertical-align:top; width:68.95pt"><p>&nbsp;</p></td></tr><tr><td style="background-color:#d0dbf0; height:20.95pt; width:96.7pt"><p style="margin-left:5.4pt; margin-right:0in">Quincke oedema</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:5.4pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:5.4pt; margin-right:0in">Very rare</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:1.0in"><p>&nbsp;</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:68.95pt"><p>&nbsp;</p></td></tr><tr><td rowspan="8" style="border-color:#4472c4; height:20.95pt; vertical-align:top; width:94.0pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.85pt; margin-right:4.25pt; text-align:justify">Musculoskeletal and connective tissue disorders</p></td><td style="height:20.95pt; vertical-align:top; width:96.7pt"><p style="margin-left:9.9pt; margin-right:0in">Arthralgia</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="background-color:#d0dbf0; height:20.95pt; width:96.7pt"><p style="margin-left:9.9pt; margin-right:0in">Back pain</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:96.7pt"><p style="margin-left:9.9pt; margin-right:0in">Joint swelling</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="background-color:#d0dbf0; height:34.7pt; width:96.7pt"><p style="margin-left:9.9pt; margin-right:0in">Muscle spasm</p></td><td style="background-color:#d0dbf0; height:34.7pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:34.7pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:34.7pt; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:34.7pt; width:68.95pt"><p style="margin-left:9.9pt; margin-right:24.35pt">Not known</p></td></tr><tr><td style="height:34.75pt; vertical-align:top; width:96.7pt"><p style="margin-left:9.9pt; margin-right:38.8pt">Muscular weakness</p></td><td style="height:34.75pt; vertical-align:top; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="height:34.75pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="background-color:#d0dbf0; height:20.95pt; width:96.7pt"><p style="margin-left:9.9pt; margin-right:0in">Myalgia</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">Not known</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:96.7pt"><p style="margin-left:0in; margin-right:8.95pt; text-align:right">Pain in extremit</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="background-color:#d0dbf0; height:20.95pt; width:96.7pt"><p style="margin-left:0in; margin-right:12.7pt; text-align:right">Ankle swelling</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">Common</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td rowspan="7" style="border-color:#4472c4; height:34.7pt; vertical-align:top; width:94.0pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.85pt; margin-right:4.3pt">Renal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and urinary disorders</p></td><td style="height:34.7pt; vertical-align:top; width:96.7pt"><p style="margin-left:9.9pt">Blood creatinine increased</p></td><td style="height:34.7pt; vertical-align:top; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="height:34.7pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:34.7pt; vertical-align:top; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">Not known</p></td><td style="height:34.7pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="background-color:#d0dbf0; height:34.75pt; width:96.7pt"><p style="margin-left:9.9pt; margin-right:30.1pt">Micturition disorder</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:96.7pt"><p style="margin-left:9.9pt; margin-right:0in">Nocturia</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="background-color:#d0dbf0; height:20.95pt; width:96.7pt"><p style="margin-left:9.9pt; margin-right:0in">Pollakiuria</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">common</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="height:34.75pt; vertical-align:top; width:96.7pt"><p style="margin-left:9.9pt; margin-right:28.1pt">Renal dysfunction</p></td><td style="height:34.75pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt; margin-right:24.35pt">Not known</p></td></tr><tr><td style="background-color:#d0dbf0; height:34.65pt; width:96.7pt"><p style="margin-left:9.9pt; margin-right:4.2pt">Acute&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renal failure</p></td><td style="background-color:#d0dbf0; height:34.65pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:34.65pt; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:34.65pt; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:34.65pt; width:68.95pt"><p style="margin-left:9.9pt; margin-right:24.35pt">Not known</p></td></tr><tr><td style="height:34.75pt; vertical-align:top; width:96.7pt"><p style="margin-left:9.9pt; margin-right:4.2pt">Renal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; failure and impairment</p></td><td style="height:34.75pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">Not known</p></td><td style="height:34.75pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">Rare</p></td></tr><tr><td rowspan="2" style="background-color:#d0dbf0; border-color:#4472c4; height:20.95pt; width:94.0pt"><p style="margin-left:9.85pt; margin-right:4.3pt">Reproductive system&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and breast disorders</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:96.7pt"><p style="margin-left:9.9pt; margin-right:0in">Impotence</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:1.0in"><p>&nbsp;</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">Common</p></td></tr><tr><td style="height:26.55pt; vertical-align:top; width:96.7pt"><p style="margin-left:0in; margin-right:11.65pt; text-align:right">Gynaecomastia</p></td><td style="height:26.55pt; vertical-align:top; width:87.05pt"><p>&nbsp;</p></td><td style="height:26.55pt; vertical-align:top; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="height:26.55pt; vertical-align:top; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:26.55pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td rowspan="2" style="border-color:#4472c4; height:34.75pt; vertical-align:top; width:94.0pt"><p style="margin-left:9.85pt; margin-right:4.3pt">General disorders&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and administration</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:96.7pt"><p style="margin-left:9.9pt; margin-right:4.25pt">Abasia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gait disturbance</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:96.7pt"><p style="margin-left:9.9pt">Asthenia</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p style="margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p style="margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:1.0in"><p style="margin-left:9.9pt">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">Not</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="7" style="border-color:#4472c4; height:20.95pt; vertical-align:top; width:94.0pt"><p style="margin-left:9.85pt">site conditions</p></td><td style="border-color:#4472c4; height:20.95pt; vertical-align:top; width:96.7pt"><p>&nbsp;</p></td><td style="border-color:#4472c4; height:20.95pt; vertical-align:top; width:87.05pt"><p>&nbsp;</p></td><td style="border-color:#4472c4; height:20.95pt; vertical-align:top; width:87.05pt"><p>&nbsp;</p></td><td style="border-color:#4472c4; height:20.95pt; vertical-align:top; width:1.0in"><p>&nbsp;</p></td><td style="border-color:#4472c4; height:20.95pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt">known</p></td></tr><tr><td style="background-color:#d0dbf0; height:34.7pt; width:96.7pt"><p style="margin-left:9.9pt; margin-right:27.1pt">Discomfort, malaise</p></td><td style="background-color:#d0dbf0; height:34.7pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:34.7pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:34.7pt; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:34.7pt; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:96.7pt"><p style="margin-left:9.9pt; margin-right:0in">Fatigue</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">Common</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">Common</p></td><td style="height:20.95pt; vertical-align:top; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">Uncommon</p></td><td style="height:20.95pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="background-color:#d0dbf0; height:34.75pt; width:96.7pt"><p style="margin-left:9.9pt; margin-right:4.2pt">Non&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cardiac chest pain</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:96.7pt"><p style="margin-left:5.4pt; margin-right:0in">Oedema</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p style="margin-left:5.4pt; margin-right:0in">Common</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p style="margin-left:5.4pt; margin-right:0in">Common</p></td><td style="height:20.95pt; vertical-align:top; width:1.0in"><p style="margin-left:5.4pt; margin-right:0in">--</p></td><td style="height:20.95pt; vertical-align:top; width:68.95pt"><p style="margin-left:5.4pt; margin-right:0in">--</p></td></tr><tr><td style="background-color:#d0dbf0; height:20.95pt; width:96.7pt"><p style="margin-left:5.4pt; margin-right:0in">Pain</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:5.4pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:5.4pt; margin-right:0in">Uncommon</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:1.0in"><p style="margin-left:5.4pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:68.95pt"><p style="margin-left:5.4pt; margin-right:0in">--</p></td></tr><tr><td style="height:20.85pt; vertical-align:top; width:96.7pt"><p style="margin-left:5.4pt">Pyrexia</p></td><td style="height:20.85pt; vertical-align:top; width:87.05pt"><p style="margin-left:5.4pt">--</p></td><td style="height:20.85pt; vertical-align:top; width:87.05pt"><p style="margin-left:5.4pt">--</p></td><td style="height:20.85pt; vertical-align:top; width:1.0in"><p style="margin-left:5.4pt">--</p></td><td style="height:20.85pt; vertical-align:top; width:68.95pt"><p style="margin-left:5.4pt">Not known</p></td></tr><tr><td rowspan="8" style="background-color:#d0dbf0; border-color:#4472c4; height:34.75pt; width:94.0pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.85pt; margin-right:0in">Investigations</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:96.7pt"><p style="margin-left:0in; margin-right:6.65pt; text-align:right">Lipids increased</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:87.05pt"><p>&nbsp;</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:1.0in"><p>&nbsp;</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:68.95pt"><p style="margin-left:9.9pt; margin-right:15.05pt">Very common</p></td></tr><tr><td style="height:48.55pt; vertical-align:top; width:96.7pt"><p style="margin-left:9.9pt; margin-right:4.2pt">Blood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urea nitrogen increased</p></td><td style="height:48.55pt; vertical-align:top; width:87.05pt"><p>&nbsp;</p><p style="margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="height:48.55pt; vertical-align:top; width:87.05pt"><p>&nbsp;</p><p style="margin-left:9.9pt">--</p></td><td style="height:48.55pt; vertical-align:top; width:1.0in"><p>&nbsp;</p><p style="margin-left:9.9pt">--</p></td><td style="height:48.55pt; vertical-align:top; width:68.95pt"><p>&nbsp;</p><p style="margin-left:9.9pt">--</p></td></tr><tr><td style="background-color:#d0dbf0; height:34.75pt; width:96.7pt"><p style="margin-left:9.9pt; margin-right:7.45pt">Blood uric acid increased</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:34.75pt; width:68.95pt"><p>&nbsp;</p></td></tr><tr><td style="height:20.95pt; vertical-align:top; width:96.7pt"><p style="margin-left:9.9pt">Glycosuria</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p>&nbsp;</p></td><td style="height:20.95pt; vertical-align:top; width:87.05pt"><p>&nbsp;</p></td><td style="height:20.95pt; vertical-align:top; width:1.0in"><p>&nbsp;</p></td><td style="height:20.95pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt">Rare</p></td></tr><tr><td style="background-color:#d0dbf0; height:34.65pt; width:96.7pt"><p style="margin-left:9.9pt; margin-right:3.75pt">Blood potassium decreased</p></td><td style="background-color:#d0dbf0; height:34.65pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:34.65pt; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:34.65pt; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:34.65pt; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="height:34.75pt; vertical-align:top; width:96.7pt"><p style="margin-left:9.9pt; margin-right:3.75pt">Blood potassium increased</p></td><td style="height:34.75pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:34.75pt; vertical-align:top; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">Not known</p></td><td style="height:34.75pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="background-color:#d0dbf0; height:20.95pt; width:96.7pt"><p style="margin-left:0in; margin-right:8.0pt; text-align:right">Weight increase</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="background-color:#d0dbf0; height:20.95pt; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr><tr><td style="height:21.0pt; vertical-align:top; width:96.7pt"><p style="margin-left:0in; margin-right:6.0pt; text-align:right">Weight decrease</p></td><td style="height:21.0pt; vertical-align:top; width:87.05pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:21.0pt; vertical-align:top; width:87.05pt"><p style="margin-left:0in; margin-right:19.3pt; text-align:right">Uncommon</p></td><td style="height:21.0pt; vertical-align:top; width:1.0in"><p style="margin-left:9.9pt; margin-right:0in">--</p></td><td style="height:21.0pt; vertical-align:top; width:68.95pt"><p style="margin-left:9.9pt; margin-right:0in">--</p></td></tr></tbody></table><p style="margin-right:175.8pt; text-align:justify">* See section 4.4 Photosensitivity ** Mostly consistent with cholestasis Description of selected adverse reactions</p><p style="margin-right:11.35pt; text-align:justify">Non-melanoma skin cancer: based on available data from epidemiological studies, cumulative dose- dependent association between hydrochlorothiazide and NMSC has been observed (see also sections 4.4 and 5.1).</p><p style="text-align:justify">Reporting of suspected adverse reactions</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>Reporting of suspected adverse reactions</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p style="margin-left:12.7pt; margin-right:0in; text-indent:-.1in"><!--[if !supportLists]-->&bull;&nbsp;&nbsp; <!--[endif]--><strong>Saudi Arabia:</strong></p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p style="margin-right:210.05pt">The National Pharmacovigilance and Drug Safety Centre (NPC) Fax: +966-11-205-7662</p><p style="margin-right:368.2pt">Call NPC at +966-11-2038222, Ext: 2317-2356-2353-2340.</p><p>Reporting hotline: 19999</p><p style="margin-right:369.7pt">E-mail: npc.drug@sfda.gov.sa Website: www.sfda.gov.sa/npc</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp; <!--[endif]-->Other GCC States:</p><p>&minus; Please contact the relevant competent authority.</p><p style="margin-left:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">There is no experience of overdose with Vittoria HCT. The major symptom of overdose with valsartan is possibly pronounced hypotension with dizziness. Overdose with amlodipine may result in excessive peripheral vasodilation and, possibly, reflex tachycardia. Marked and potentially prolonged systemic hypotension, including shock with fatal outcome, have been reported with amlodipine.</p><p style="margin-left:0in">&nbsp;</p><p><u>Treatment</u></p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify"><em><u>Amlodipine/Valsartan/Hydrochlorothiazide</u> </em>Clinically significant hypotension due to Vittoria HCT overdose calls for active cardiovascular support, including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify"><em><u>Amlodipine</u> </em>If ingestion is recent, induction of vomiting or gastric lavage may be considered. Administration of activated charcoal to healthy volunteers immediately or up to two hours after ingestion of amlodipine has been shown to significantly decrease amlodipine absorption. Amlodipine is unlikely to be removed by haemodialysis.</p><p style="margin-left:0in">&nbsp;</p><p><em><u>Valsartan</u> </em>Valsartan is unlikely to be removed by haemodialysis.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify"><em><u>Hydrochlorothiazide</u> </em>Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloraemia) and hypovolaemia resulting from excessive diuresis. The most common signs and symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasms and or accentuate arrhythmia associated with the concomitant use of digitalis glycosides or certain anti- arrhythmic medicinal products. The degree to which hydrochlorothiazide is removed by haemodialysis has not been established.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Pharmacotherapeutic group: Agents acting on the renin-angiotensin system, angiotensin II antagonists, other combinations, ATC code: C09DX01.</p><p style="text-align:justify">Mechanism of action</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Vittoria HCT combines three antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines and hydrochlorothiazide belongs to the thiazide diuretics class of medicines. The combination of these substances has an additive antihypertensive effect.</p><p><u>Amlodipine/Valsartan/Hydrochlorothiazide</u></p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">Clinical efficacy and safety Vittoria HCT was studied in a double-blind, active controlled study in hypertensive patients. A total of 2,271 patients with moderate to severe hypertension (mean baseline systolic/diastolic blood pressure was 170/107 mmHg) received treatments of amlodipine/valsartan/hydrochlorothiazide 10 mg/320 mg/25 mg, valsartan/hydrochlorothiazide 320 mg/25 mg, amlodipine/valsartan 10 mg/320 mg, or hydrochlorothiazide/amlodipine 25 mg/10 mg. At study initiation patients were assigned lower doses of their treatment combination and were titrated to their full treatment dose by week 2.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">At week 8, the mean reductions in systolic/diastolic blood pressure were 39.7/24.7 mmHg with Vittoria HCT, 32.0/19.7 mmHg with valsartan/hydrochlorothiazide, 33.5/21.5 mmHg with amlodipine/valsartan, and 31.5/19.5 mmHg with amlodipine/hydrochlorothiazide. The triple combination therapy was statistically superior to each of the three dual combination treatments in reduction of diastolic and</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">systolic blood pressures. The reductions in systolic/diastolic blood pressure with Vittoria HCT were 7.6/5.0 mmHg greater than with valsartan/hydrochlorothiazide, 6.2/3.3 mmHg greater than with amlodipine/valsartan, and 8.2/5.3 mmHg greater than with amlodipine/hydrochlorothiazide. The full blood pressure lowering effect was achieved 2 weeks after being on their maximal dose of Vittoria HCT. Statistically greater proportions of patients achieved blood pressure control (&lt;140/90 mmHg) with Vittoria HCT (71%) compared to each of the three dual combination therapies (45-54%) (p&lt;0.0001).</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify">In a subgroup of 283 patients focusing on ambulatory blood pressure monitoring, clinically and statistically superior reductions in 24-hour systolic and diastolic blood pressures were observed with the triple combination compared to valsartan/hydrochlorothiazide, valsartan/amlodipine, and hydrochlorothiazide/amlodipine.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><u>Amlodipine</u></p><p style="margin-left:5.5pt; margin-right:11.35pt; text-align:justify">Mechanism of action the amlodipine component of Vittoria HCT inhibits the transmembrane entry of calcium ions into cardiac and vascular smooth muscle. The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle, causing reductions in peripheral vascular resistance and in blood pressure.</p><p style="margin-right:11.3pt; text-align:justify">Pharmacodynamic effects Experimental data suggest that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.</p><p style="margin-right:11.3pt; text-align:justify">Following administration of therapeutic doses to patients with hypertension, amlodipine produces vasodilation, resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing.</p><p style="margin-left:0in">&nbsp;</p><p style="text-align:justify">Plasma concentrations correlate with effect in both young and elderly patients.</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and increases in glomerular filtration rate and effective renal plasma flow, without change in filtration fraction or proteinuria.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">As with other calcium channel blockers, haemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have generally demonstrated a small increase in cardiac index without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. In haemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and humans, even when co-administered with beta blockers to humans.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.25pt; text-align:justify">Amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals or humans. In clinical studies in which amlodipine was administered in combination with beta blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters were observed.</p><p style="margin-right:11.35pt; text-align:justify">Amlodipine has been studied in patients with chronic stable angina, vasospastic angina and angiographically documented coronary artery disease.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="text-align:justify">Clinical efficacy and safety</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">Use in patients with hypertension A randomised double-blind morbidity-mortality study called the Antihypertensive and LipidLowering treatment to prevent Heart Attack Trial (ALLHAT) was performed to compare newer therapies: amlodipine 2.5-10 mg/day (calcium channel blocker) or lisinopril 10-40 mg/day (ACEinhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/day in mild to moderate hypertension.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify">A total of 33,357 hypertensive patients aged 55 or older were randomised and followed for a mean of 4.9 years. The patients had at least one additional coronary heart disease risk factor, including: previous myocardial infarction or stroke (&gt;6 months prior to enrollment) or documentation of other atherosclerotic cardiovascular disease (overall 51.5%), type 2 diabetes (36.1%), high density lipoprotein - cholesterol</p><p style="margin-right:11.35pt; text-align:justify">&lt;35 mg/dl or &lt;0.906 mmol/l (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.4pt; text-align:justify">The primary endpoint was a composite of fatal coronary heart disease or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">chlorthalidone-based therapy: risk ratio (RR) 0.98 95% CI (0.90-1.07) p=0.65. Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% versus 7.7%, RR 1.38, 95% CI [1.25-1.52] p&lt;0.001). However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy RR 0.96 95% CI [0.89- 1.02] p=0.20.</p><p style="margin-left:0in">&nbsp;</p><p>Valsartan</p><p style="margin-left:5.5pt; margin-right:11.35pt; text-align:justify">Mechanism of action Valsartan is an orally active, potent and specific angiotensin II receptor antagonist. It acts selectively on the receptor subtype AT1, which is responsible for the known actions of angiotensin II.</p><p style="margin-right:11.3pt; text-align:justify">Clinical efficacy and safety Administration of valsartan to patients with hypertension results in a drop in blood pressure without affecting pulse rate.</p><p style="margin-right:11.3pt; text-align:justify">In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak drop in blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after administration. During repeated administration, the maximum reduction in blood pressure with any dose is generally attained within 2-4 weeks.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Hydrochlorothiazide</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">Mechanism of action the site of action of thiazide diuretics is primarily in the renal distal convoluted tubule. It has been shown that there is a high-affinity receptor in the renal cortex as the primary binding site for the thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule. The mode of action of thiazides is through inhibition of the Na+Cl- symporter perhaps by competing for the Cl- site, thereby affecting electrolyte reabsorption mechanisms: directly increasing sodium and chloride excretion to an approximately equal extent, and indirectly, by this diuretic action, reducing plasma volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and a decrease in serum potassium.</p><p style="margin-right:11.3pt; text-align:justify">Non-melanoma skin cancer based on available data from epidemiological studies, cumulative dose- dependent association between hydrochlorothiazide and NMSC has been observed. One study included a population comprised of 71,533 cases of BCC and of 8,629 cases of SCC matched to 1,430,833 and</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">172,462 population controls, respectively. High hydrochlorothiazide use (&ge;50000 mg cumulative) was associated with an adjusted odds ratio (OR) of 1.29 (95% CI: 1.23-1.35) for BCC and 3.98 (95% CI: 3.68-4.31) for SCC. A clear cumulative dose response relationship was observed for both BCC and SCC. Another study showed a possible association between lip cancer (SCC) and exposure to hydrochlorothiazide: 633 cases of lip cancer were matched with 63,067 population controls, using a risk- set sampling strategy. A cumulative dose-response relationship was demonstrated with an adjusted OR 2.1 (95% CI: 1.7-2.6) increasing to OR 3.9 (3.0-4.9) for high use (~25000 mg) and OR 7.7 (5.7-10.5) for the highest cumulative dose (~100000 mg) (see also section 4.4).</p><p style="margin-left:0in">&nbsp;</p><p style="text-align:justify">Paediatric population</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">The European Medicines Agency has waived the obligation to submit the results of studies with Vittoria HCT in all subsets of the paediatric population in essential hypertension (see section 4.2 for information on paediatric use).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="text-align:justify">Other: dual blockade of the renin-angiotensin-aldosterone system (RAAS)</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify">Two large randomised, controlled trials (ONTARGET [ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial] and VA NEPHRON-D [The Veterans Affairs Nephropathy in Diabetes]) have examined the use of the combination of an ACE inhibitor with an ARB.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.35pt; text-align:justify">ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHROND was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.25pt; text-align:justify">These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE inhibitors and ARBs.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify">ACE inhibitors and ARBs should therefore not be used concomitantly in patients with diabetic nephropathy (see section 4.4).</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify; text-indent:3.0pt">ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or an ARB in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">Pharmacotherapeutic group: Agents acting on the renin-angiotensin system, angiotensin II antagonists, other combinations, ATC code: C09DX01.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:0in; text-align:justify"><strong><u>Mechanism of action</u></strong></p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">Vittoria HCT combines three antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines and hydrochlorothiazide belongs to the thiazide diuretics class of medicines. The combination of these substances has an additive antihypertensive effect.</p><p style="margin-left:0in">&nbsp;</p><p>Amlodipine/Valsartan/Hydrochlorothiazide</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">Clinical efficacy and safety Vittoria HCT was studied in a double-blind, active controlled study in hypertensive patients. A total of 2,271 patients with moderate to severe hypertension (mean baseline systolic/diastolic blood pressure was 170/107 mmHg) received treatments of amlodipine/valsartan/hydrochlorothiazide 10 mg/320 mg/25 mg, valsartan/hydrochlorothiazide 320 mg/25 mg, amlodipine/valsartan 10 mg/320 mg, or hydrochlorothiazide/amlodipine 25 mg/10 mg. At study initiation patients were assigned lower doses of their treatment combination and were titrated to their full treatment dose by week 2.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.25pt; text-align:justify">At week 8, the mean reductions in systolic/diastolic blood pressure were 39.7/24.7 mmHg with Vittoria HCT, 32.0/19.7 mmHg with valsartan/hydrochlorothiazide, 33.5/21.5 mmHg with amlodipine/valsartan, and 31.5/19.5 mmHg with amlodipine/hydrochlorothiazide. The triple combination therapy was</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">statistically superior to each of the three dual combination treatments in reduction of diastolic and systolic blood pressures. The reductions in systolic/diastolic blood pressure with Vittoria HCT were 7.6/5.0 mmHg greater than with valsartan/hydrochlorothiazide, 6.2/3.3 mmHg greater than with amlodipine/valsartan, and 8.2/5.3 mmHg greater than with amlodipine/hydrochlorothiazide. The full blood pressure lowering effect was achieved 2 weeks after being on their maximal dose of Vittoria HCT. Statistically greater proportions of patients achieved blood pressure control (&lt;140/90 mmHg) with Vittoria HCT (71%) compared to each of the three dual combination therapies (45-54%) (p&lt;0.0001).</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify">In a subgroup of 283 patients focusing on ambulatory blood pressure monitoring, clinically and statistically superior reductions in 24-hour systolic and diastolic blood pressures were observed with the triple combination compared to valsartan/hydrochlorothiazide, valsartan/amlodipine, and hydrochlorothiazide/amlodipine.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Amlodipine</p><p style="margin-left:5.5pt; margin-right:11.35pt; text-align:justify">Mechanism of action The amlodipine component of Vittoria HCT inhibits the transmembrane entry of calcium ions into cardiac and vascular smooth muscle. The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle, causing reductions in peripheral vascular resistance and in blood pressure.</p><p style="margin-right:11.25pt; text-align:justify">Pharmacodynamic effects Experimental data suggest that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.</p><p style="margin-right:11.25pt; text-align:justify">Following administration of therapeutic doses to patients with hypertension, amlodipine produces vasodilation, resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing.</p><p style="text-align:justify">Plasma concentrations correlate with effect in both young and elderly patients.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and increases in glomerular filtration rate and effective renal plasma flow, without change in filtration fraction or proteinuria.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify">As with other calcium channel blockers, haemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have generally demonstrated a small increase in cardiac index without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. In haemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and humans, even when co-administered with beta blockers to humans.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">Amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals or humans. In clinical studies in which amlodipine was administered in combination with beta blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters were observed.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.35pt; text-align:justify">Amlodipine has been studied in patients with chronic stable angina, vasospastic angina and angiographically documented coronary artery disease.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.25pt; text-align:justify">Clinical efficacy and safety Use in patients with hypertension A randomised double-blind morbidity- mortality study called the Antihypertensive and LipidLowering treatment to prevent Heart Attack Trial (ALLHAT) was performed to compare newer therapies: amlodipine 2.5-10 mg/day (calcium channel blocker) or lisinopril 10-40 mg/day (ACEinhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/day in mild to moderate hypertension.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify">A total of 33,357 hypertensive patients aged 55 or older were randomised and followed for a mean of 4.9 years. The patients had at least one additional coronary heart disease risk factor, including: previous myocardial infarction or stroke (&gt;6 months prior to enrollment) or documentation of other atherosclerotic cardiovascular disease (overall 51.5%), type 2 diabetes (36.1%), high density lipoprotein - cholesterol</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.4pt; text-align:justify">&lt;35 mg/dl or &lt;0.906 mmol/l (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.25pt; text-align:justify">The primary endpoint was a composite of fatal coronary heart disease or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: risk ratio (RR) 0.98 95% CI (0.90-1.07) p=0.65. Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% versus 7.7%, RR 1.38, 95% CI [1.25-1.52] p&lt;0.001). However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy RR 0.96 95% CI [0.89- 1.02] p=0.20.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Valsartan</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Mechanism of action Valsartan is an orally active, potent and specific angiotensin II receptor antagonist. It acts selectively on the receptor subtype AT1, which is responsible for the known actions of angiotensin II.</p><p style="margin-right:11.35pt; text-align:justify">Clinical efficacy and safety Administration of valsartan to patients with hypertension results in a drop in blood pressure without affecting pulse rate.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.25pt; text-align:justify">In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak drop in blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after administration. During repeated administration, the maximum reduction in blood pressure with any dose is generally attained within 2-4 weeks.</p><p style="margin-left:0in">&nbsp;</p><p>Hydrochlorothiazide</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Mechanism of action The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule. It has been shown that there is a high-affinity receptor in the renal cortex as the primary binding site for the thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule. The mode of action of thiazides is through inhibition of the Na+Cl- symporter perhaps by competing for the Cl- site, thereby affecting electrolyte reabsorption mechanisms: directly increasing sodium and chloride</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">excretion to an approximately equal extent, and indirectly, by this diuretic action, reducing plasma volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and a decrease in serum potassium.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify">Non-melanoma skin cancer Based on available data from epidemiological studies, cumulative dose- dependent association between hydrochlorothiazide and NMSC has been observed. One study included a population comprised of 71,533 cases of BCC and of 8,629 cases of SCC matched to 1,430,833 and 172,462 population controls, respectively. High hydrochlorothiazide use (&ge;50000 mg cumulative) was associated with an adjusted odds ratio (OR) of 1.29 (95% CI: 1.23-1.35) for BCC and 3.98 (95% CI: 3.68-4.31) for SCC. A clear cumulative dose response relationship was observed for both BCC and SCC. Another study showed a possible association between lip cancer (SCC) and exposure to hydrochlorothiazide: 633 cases of lip cancer were matched with 63,067 population controls, using a risk- set sampling strategy. A cumulative dose-response relationship was demonstrated with an adjusted OR 2.1 (95% CI: 1.7-2.6) increasing to OR 3.9 (3.0-4.9) for high use (~25000 mg) and OR 7.7 (5.7-10.5) for the highest cumulative dose (~100000 mg) (see also section 4.4).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="text-align:justify">Paediatric population</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">The European Medicines Agency has waived the obligation to submit the results of studies with Vittoria HCT in all subsets of the paediatric population in essential hypertension (see section 4.2 for information on paediatric use).</p><p style="text-align:justify">Other: dual blockade of the renin-angiotensin-aldosterone system (RAAS)</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">Two large randomised, controlled trials (ONTARGET [ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial] and VA NEPHRON-D [The Veterans Affairs Nephropathy in Diabetes]) have examined the use of the combination of an ACE inhibitor with an ARB.</p><p style="margin-right:11.35pt; text-align:justify">ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHROND was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify">These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE inhibitors and ARBs.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify">ACE inhibitors and ARBs should therefore not be used concomitantly in patients with diabetic nephropathy (see section 4.4).</p><p style="margin-right:11.3pt; text-align:justify; text-indent:3.0pt">ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or an ARB in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Amlodipine/Valsartan/Hydrochlorothiazide</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify">In a variety of preclinical safety studies conducted in several animal species with amlodipine, valsartan, hydrochlorothiazide,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; valsartan/hydrochlorothiazide,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amlodipine/valsartan&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and amlodipine/valsartan/hydrochlorothiazide (Vittoria HCT), there was no evidence of systemic or target organ toxicity that would adversely affect the development of Vittoria HCT for clinical use in humans.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.25pt; text-align:justify">Preclinical safety studies of up to 13 weeks in duration were conducted with amlodipine/valsartan/hydrochlorothiazide in rats. The combination resulted in expected reduction of red blood cell mass (erythrocytes, haemoglobin, haematocrit, and reticulocytes), increase in serum urea, increase in serum creatinine, increase in serum potassium, juxtaglomerular (JG) hyperplasia in the kidney and focal erosions in the glandular stomach in rats. All these changes were reversible after a 4-week recovery period and were considered to be exaggerated pharmacological effects.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:11.25pt; text-align:justify">The amlodipine/valsartan/hydrochlorothiazide combination was not tested for genotoxicity or carcinogenicity as there was no evidence of any interaction between these substances, which have been on the market for a long time. However, amlodipine, valsartan and hydrochlorothiazide have been tested individually for genotoxicity and carcinogenicity with negative results.</p><p style="margin-left:0in">&nbsp;</p><p>Amlodipine</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:11.25pt; text-align:justify"><u>Reproductive toxicology</u> Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.5pt; margin-right:11.3pt; text-align:justify; text-indent:3.0pt"><u>Impairment of fertility</u> There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify"><u>Carcinogenesis</u>, mutagenesis Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m2 basis) was close to the maximum tolerated dose for mice but not for rats.</p><p style="margin-left:0in">&nbsp;</p><p style="text-align:justify">Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:351.35pt">* Based on patient weight of 50 kg<u> Valsartan</u></p><p style="margin-right:11.3pt; text-align:justify">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify">In rats, maternally toxic doses (600 mg/kg/day) during the last days of gestation and lactation led to&nbsp; lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify">In non-clinical safety studies, high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised blood urea nitrogen, and renal tubular hyperplasia and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60- kg patient).</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.3pt; text-align:justify">In marmosets at comparable doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy including raised blood urea nitrogen and creatinine.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:11.35pt; text-align:justify">Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were considered to be caused by the pharmacological action of valsartan which produces prolonged hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.5pt; margin-right:0in"><strong>Vittoria HCT &trade; 10/160/25 mg Film Coated Tablets:</strong></p><p style="margin-right:394.0pt">Microcrystalline cellulose Crospovidone</p><p style="margin-right:387.7pt">Colloidal silicon dioxide Magnesium stearate Opadry 03F220064 Yellow Purified Water</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Vittoria HCT &trade; 5/160/25 mg Film Coated Tablets:</p><p style="margin-right:394.0pt">Microcrystalline cellulose Crospovidone</p><p style="margin-right:387.7pt">Colloidal silicon dioxide Magnesium stearate Opadry 03F220066 Yellow Purified Water</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Vittoria HCT &trade; 5/160/12.5 mg Film Coated Tablets:</p><p style="margin-right:394.0pt">Microcrystalline cellulose Crospovidone</p><p style="margin-right:401.35pt">Colloidal silicon dioxide Magnesium stearate Iron Oxide Yellow</p><p style="margin-left:5.5pt; margin-right:387.0pt">Opadry 03F280024 Yellow Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:8.5pt; margin-right:0in">Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:8.5pt; margin-right:0in">Do not store above 30&deg; C. Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vittoria HCT &trade; tablet are available in the following packs:</p><p>10/160/25 mg are available in a box of 4 blisters, 7 tablets per each blister.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>5/160/25 mg are available in a box of 4 blisters, 7 tablets per each blister. 5/160/12.5 mg are available in a box of 4 blisters, 7 tablets per each blister. Not all packs may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:14.5pt; margin-right:0in">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
P.O. Box 6267
Jeddah 21442, Saudi Arabia. Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com Website: www.jamjoompharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novmber 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>